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The need for iodide in biology is almost exclusively limited to its role in 
thyroid hormones, yet the recycling of thyroidal iodide is still critical for human 
health.  The flavoprotein iodotyrosine deiodinase (IYD) salvages iodide from 
byproducts (mono- and diiodotyrosine, MIT and DIT) of thyroid hormone 
biosynthesis.  The original proposal for the deiodination mechanism of IYD included 
a nucleophilic attack on the iodo group by an active site cysteine.  Although this 
proposal had strong precedence, site-directed mutagenesis has now proven this 
wrong.  Further investigation of the IYD mechanism required large scale protein 
expression and isolation.  This was stymied by the lack of a convenient isolation 
system until a truncated and soluble version of wild-type IYD could be expressed in 
yeast and insect cells.   
Large scale isolation of this soluble enzyme derivative provided the necessary 
material for crystallographic studies that in turn resulted in a structure of IYD at 2.0 Å 
  
resolution.  The structure verified IYD’s assignment in the NAD(P)H oxidase/flavin 
reductase superfamily and showed that no cysteine residues were in the active site.  
Structures of IYD with bound MIT and DIT were also obtained and indicated that 
these substrates are sequestered within the active site by inducing helical structure in 
two otherwise disordered regions of the enzyme to form an active site lid.  This lid 
confers substrate specificity and is critical in positioning substrate such that it stacks 
on the isoalloxazine of the flavin mononucleotide (FMN) cofactor.  Further 
investigation identified 3-bromo and 3-chlorotyrosine as substrates for IYD, while 3-
fluorotyrosine was not dehalogenated by IYD.  These new substrates illustrate IYD’s 
activity as a general dehalogenase and IYD’s strong dehalogenating power.  
Mechanistic studies utilizing 5-deazaFMN, which is incapable of performing 1 
electron processes, indicated that IYD dehalogenation occurs via two sequential 1 
electron transfers from reduced FMN to substrate.  Anaerobic single turnover assays 
and mechanistic precedence have led to a likely mechanism of dehalogenation for 
IYD involving substrate tautomerization followed by injection of an electron into the 
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Chapter 1: Introduction to iodotyrosine deiodinase 
 
1.1 Iodine is a precious element in thyroxine biosynthesis  
The element iodine is primarily found in seawater; however, it plays a critical 
role in physiology.  The element’s association with human physiology was 
recognized only nine years after its first discovery (1).  This occurred in 1820 when 
Coindet announced that iodine treatment could reduce the size of goiters in patients 
(1).  Almost a century later, iodine’s biological role was finally ascribed to its 
incorporation into the thyroid hormone thyroxine or T4 (Figure 1-1) (2).  T4 is 
essential in regulating intermediary metabolism in nearly all tissues (3-5).  It is 
considered a prohormone with its regulatory action occurring via deiodination to its  



































iodothyronine deiodinase (ID) (5-7).  T4 and its derivatives affect a number of 
physiological processes including protein synthesis, fat and carbohydrate metabolism, 
obligatory heat production, as well as growth and development (3, 8). 
Biosynthesis of T4 occurs over several steps (Figure 1-2) (4, 9, 10) and is 
promoted by thyroid stimulating hormone (11).  First, iodide is procured from the 
blood stream across the basal cell membrane of thyroid follicular cells by the Na+/I- 



























Figure 1-2. T4 biosynthesis. 













membrane by NIS (13).  This pool of iodide is then incorporated at the 3- and/or 5-
position of specific tyrosine (Tyr) residues of the thyroidal protein thyroglobulin (TG) 
(14, 15).  Thyroid peroxidase is responsible for this iodination as well as the next step 
in biosynthesis for which the 3-monoiodinated and/or 3,5-diiodinated tyrosine side 
chains of TG are coupled to form the basis of T4 or T3 (16).  The now mature TG is 
stored in the extracellular colloid until needed.  In order to secrete T4, mature TG is 
taken up in the follicular cells by endocytosis into small microsome vesicles where it 
is then proteolyzed.  This releases free T4 and T3, as well as significant amounts of the 
uncoupled iodinated tyrosines 3-mono- and 3,5-diiodotyrosines (MIT and DIT, 
respectively) which are byproducts of T4 biosynthesis.  Lastly, T4 and T3 are 
transported from the thyroid cell into the bloodstream where they circulate and act on 
cells distant from the thyroid (17, 18).                 
Iodide is scarce in the environment, especially in landlocked areas which lack 
accessibility to the sea.  Insufficient levels of the micronutrient iodide limit T4 
biosynthesis which can subsequently result in diseases like hypothyroidism and 
goiter, while more severe developmental problems including cretinism can occur (19, 
20).  Iodide deficiency is not limited to these landlocked regions (8).  In fact, it is a 
global health problem that plagues even developed countries with as many as 2 
billion people affected worldwide in 2007 according to the World Health 
Organization (21).  Interestingly, only 100-200 µg of daily dietary intake of the 
precious micronutrient is required for proper thyroid function (22).   
 The thyroid has evolved two distinct mechanisms for accumulating and 




aforementioned NIS (12, 13).  This enzyme not only sequesters iodide into follicular 
cells to levels 20 to 50 times that of normal thyroid plasma (<1 µg/mL).  The second 
mechanism involves iodide salvage from the MIT and DIT uncoupled byproducts of 
T4 biosynthesis.  The enzyme iodotyrosine deiodinase (IYD) recycles iodide from 
these byproducts by reductively dehalogenating both MIT and DIT (Figure 1-3) (23) 
but not thyroid hormones (24).  Thus, IYD allows both the liberated iodide and 
tyrosine to be reused for thyroid hormone production.  IYD activity is critical since 
MIT and DIT comprise greater than 70 % of the iodinated residues of proteolyzed TG 
(T4 or T3 comprise the other 30 %) (7, 19), and these byproducts would otherwise be 
excreted from the body along with their iodine equivalents (25).  The significance of 
IYD’s ability to recycle thyroidal iodide is well illustrated in patients first identified 
in 1956 (25-27), as well as the those reported quite recently (28, 29) who’s congenital 
goiter and/or cretinism was attributed to deiodinase deficiency. 
1.2 Iodotyrosine deiodinase is a novel flavoprotein 
The presence of an enzyme responsible for deiodinating the free iodotyrosines 














Figure 1-3. IYD catalyzes dehalogenation of MIT and DIT. 




was confirmed several years later when the absence of IYD activity was documented 
in patients with goiter and IYD activity was observed with thyroid homogenates (25-
27).  Almost two decades passed before IYD was first purified from thyroid 
homogenates and partially characterized.  The enzyme was found associated with 
microsomes existing as a 42 kilodalton (kDa) homodimer with a single flavin 
mononucleotide (FMN) cofactor (31, 32).   
Because IYD catalyzes a reductive process, turnover requires that the 
enzyme’s bound FMN cofactor be reduced.  Nicotinamide adenine dinucleotide 
phosphate (NADPH) (-317 mV (33))  has been identified as the electron donor 
utilized in IYD’s physiological reduction (23, 34).  However, solubilization of IYD 
from its native membrane resulted in loss of NADPH-responsive activity, while 
strong reducing agents like dithionite (-660 mV) which are capable of reducing IYD 
in vitro maintained deiodinase activity following enzyme solubilization (35).  This 
loss of NADPH-responsive activity upon solubilization in conjunction with the 
unusually low reduction-oxidation (redox) potential obtained for IYD (-412 mV) (32) 
resulted in the proposal that a yet unidentified reductase mediates the physiological 
reduction of IYD (36).  Moreover, the idea of a yet unidentified reductase recently 
garnered increased support when IYD displayed NADPH-responsive and dithionite 
activity in presence of human embryonic kidney 293 (HEK 293) cell lysates and only 
dithionite activity in the presence of Chinese hamster ovary (CHO) cell lysates (37, 
38).  This signified that the yet unidentified reductase or an equivalent is expressed in 




Further studies of IYD languished for several decades until the gene encoding 
IYD was identified just a few years ago (37) by serial analysis of gene expression of 
novel thyroid genes (39).  The encoded IYD protein possessed deiodinase activity 
when recombinantly expressed in mammalian cells (37).  Simultaneously, the Rokita 
lab affirmed the gene identification through protein sequencing of a porcine thyroid 
isolate exhibiting deiodinase activity (40).  IYD was predicted at the time to comprise 
an N-terminal membrane domain (residues 1-24), an intermediate domain of 
unknown structure and function (residues 25-81), and a catalytic domain (residues 82-
285) through sequence analysis (Figure 1-4) (40).   
The catalytic domain of IYD displays homology to the NAD(P)H 
oxidase/flavin reductase (NOX/FRase) superfamily of flavoproteins (40) which 
catalyze reduction of nitroaromatics and reduction of flavin substrates by an obligate 
2 electron process (41-44).  Because the catalysis of the superfamily proteins is so 
distinctive from IYD’s, they cannot be considered for precedence of IYD’s 
mechanism.  In fact, precedence for IYD’s catalysis is very limited since IYD is 
unique in that it uses a flavin to catalyze reductive dehalogenation and unusual in that 
reductive processes are generally associated with anaerobic organisms (45). 
 
 
Figure 1-4. IYD consists of a membrane anchor (residues 1-23), an intermediate 




1.3 Mechanistic precedence for IYD catalysis 
Flavin cofactors (FMN and flavin adenine dinucleotide (FAD)) are versatile 
catalysts well known for their ability to catalyze both 1 (2 x 1 e-) and 2 electron (1 x 2 













































































A) Ribityl chain 
Isoalloxazine ring 
 Figure 1-5. Flavin cofactors.  A) Flavin cofactors are commonly flavin
mononucleotide (FMN) and flavin adenine dinucleotide (FAD).  They are composed
of an isoalloxazine ring, a ribityl chain and an additional moiety attached to the
ribityl chain.  B) Reduced FMN (FMNred) can be oxidized (FMNox) by a single 2
electron oxidation or by 2 sequential 1 electron oxidation which proceed through an




fully reduced flavin, respectively.  The incorporation of flavin into proteins 
determines the cofactor’s reactivity, as residue interactions to the isoalloxazine 
influence flavin’s catalytic properties (47, 48).  This allows flavins to promote a wide 
range of reactions and are involved in a number of diverse biological processes 
including bioluminescence (49), photosynthesis (50), apoptosis (51), and even DNA 
repair (52).   
Despite flavin’s vast range of enzyme classes with which flavins are 
associated (reductases, oxygenases, electron transferases, dehydogenases, etc. (46)), 
flavoprotein precedence for reductive dehalogenation is nonexistent.  The few 
characterized flavoproteins, other than IYD, that catalyze dehalogenation are all 
monoxygenases (53-55).  These other flavin dehalogenases cannot serve as catalytic 
precedence for IYD since none perform dehalogenation in a reductive fashion.  
Additionally, only two other flavoproteins have been proposed to catalyze reductive 
dehalogenation, and minimal information is available for these enzymes (56, 57).  
Only a flavin has been implicated in their overall reaction and the net process appears 
to be reductive in nature.  Since flavin chemistry provides no precedence for IYD’s 
catalysis, precedence was sought from other catalytic processes.         
1.4 Mechanistic precedence for 2 electron reductive dehalogenation 
Reductive dehalogenation is one of the three main categories of dehalogenases 
which include hydrolytic, oxygen dependent, and reductive processes (Figure 1-6) 
(45, 58, 59).  Considerable effort has been directed in utilizing these different 




(45, 58, 59).  This has led to many dehalogenases, including reductive dehalogenases, 
being well characterized.   
The best characterized reductive dehalogenase from an aerobic organism is 
tetrachlorohydroquinone (TCHQ) dehalogenase from Sphingobium chlorophenolicum  
(60-62).  TCHQ is involved in the third and fourth steps of the pentachlorophenol 
(PCP) catabolic pathway which recently evolved to degrade the PCP pesticide.  
Catalysis by TCHQ dehalogenase relies on oxidation of glutathione for 
dehalogenation (Figure 1-7) (60).  Upon binding, the substrate is deprotonated and 
subsequently converted to a keto tautomer.  Glutathione then performs nucleophilic 
attack, which generates free chloride.  The covalent attachment of glutathione to the 
Figure 1-6. Dehalogenation by bacterial enzymes depend on either A) hydrolytic, B) 











































substrate is next broken by cysteine (Cys) 13 attack.  This releases the reduced 
product, and finally, active enzyme is regenerated by sulfide exchange with a second 
glutathione.   
Another well studied reductive dehalogenase, but not for bioremediation 
purposes, is the previously mentioned ID that catalyzes the physiological deiodination 
of thyroid hormones.  ID and IYD are the only reductive dehalogenases in mammals 
and catalyze almost equivalent reactions.  The proposed mechanism of ID (Figure 1-
8) (63, 64) initially involves the deprotonation of the substrate’s phenolic hydrogen, 
allowing tautomerization of substrate.  The selenide of an active site selenocysteine is 
responsible for dehalogenation (65, 66) through nucleophilic attack of the iodine.  
Lastly, the covalent Se-I bond is reduced by an unidentified cofactor in vivo although 
thiols can be used in vitro.         
 



















































1.5 IYD mechanism closest to precedence 
The mechanisms described in the previous section can serve as precedence for 
the mechanism of deiodination by IYD despite their lack of flavin since they all 
couple dehalogenation through an analogous reducing step.  Although IYD is a 
flavoprotein and both 1 and 2 electron transfer mechanisms should be considered, a 2 
electron mechanism is closest to the existing precedent. A tautomeric mimic of 
substrate displayed strong deiodinase inhibition (67), indicating that IYD preferably 



















































binds and stabilizes a nonaromatic intermediate similar to both TCHQ dehalogenase 
and ID.  Additionally, IYD contains 3 highly conserved Cys residues which could act 
as nucleophiles similarly to the selenide of selenocysteine in the ID mechanism (40).   
Therefore, a logical proposal for IYD’s mechanism involves a 2 electron 
transfer ultimately resulting in deiodination of substrate (Figure 1-9).  This can be 
envisioned with an initial deprotonation of the phenolic hydrogen of substrate which 
leads to tautomerization.  The sulfur of an active site Cys would then perform 
nucleophilic attack on the iodine of the intermediate.  This would break the substrate 
iodine bond, generating tyrosine and a covalent sulfenyl iodine bond.  A two electron 
reduction of this C-I bond by reduced FMN would then release free iodide, as well as 
create a covalent flavin-enzyme adduct.  Complete oxidation of the FMN would 
release the nucleophilic Cys and reduction of FMN by NADPH would subsequently 




























































1.6 Mechanistic precedence for 1 electron reductive dehalogenation 
Although the IYD deiodination mechanism closest to precedence is a 2 
electron process, 1 electron pathways must also be considered for precedence because 
IYD is a flavoprotein.  There are few examples of reductive dehalogenation where a 
radical mechanism is suggested, and they all involve a corrinoid cofactor (68, 69).  Of 
these, evidence for a radical mechanism has only been shown for tetrachloroethene 
(TCE) reductive dehalogenase (70).  Its proposed mechanism for dechlorination of 
2,3-dichloropropene (Figure 1-10) involves the reduction of substrate to a radical 
anion.  This occurs though a dissociative 1 electron transfer from a superreduced 
corrinoid cob(I)alamin.  This then facilitates chloride release and formation of a 
neutral radical which reacts with the CoII of the corrinoid to generate a covalent 
intermediate.  Protonation of this intermediate releases the 2-chloropropene product 
and the corrinoid is reduced to its resting state by iron sulfur clusters.     


























1.7 Specific aims 
IYD is an enzyme that plays a critical role in physiology, yet it remained 
poorly characterized for approximately 50 years.  Recent reports have provided a 
platform for significant advances in our understanding of IYD catalysis and reductive 
dehalogenation (37, 40).  The goal of my research was to gain an understanding of 
IYD’s catalysis at the molecular level.  Specifically, this dissertation addresses the 
following: 
1) The mechanism closest to precedence for IYD catalysis suggests the redox 
involvement of an active site Cys residue.  The requirement of Cys for IYD catalysis 
was investigated through site-directed-mutagenesis to determine if IYD catalysis does 
indeed involve Cys nucleophilic attack. 
2) Isolation of IYD in large scale had never been achieved but was essential 
for overcoming the protein folding limitations of E. coli and the cost/time restrictions 
associated with mammalian cell expression.  Thus, both yeast and insect expression 
of IYD were evaluated as sources for large scale isolation of IYD. 
3) Substituents at the 3-position of tyrosine were previously suggested to 
influence IYD substrate recognition (71, 72).  With purified enzyme, the role of 
substituents at the 3-position were directly investigated with assays for binding by 
fluorescence quenching and anaerobic single turnover.    
4) IYD could catalyze deiodination via a 1 or 2 electron transfer mechanism.  
These two possible mechanisms were distinguished by monitoring catalysis of IYD 








The mechanism closest to precedent for dehalogenation by IYD shares three 
processes with the two reductive dehalogenases TCHQ dehalogenase and ID 
discussed in detail in Chapter 1 (Figure 2-1): 1) tautomerization of substrate, 2) 
nucleophilic attack of substrate by the sulfur of cysteine or the selium of 
selenocyteine, and 3) reduction of the covalent bond formed by nucleophilic attack.  
Both TCHQ dehalogenase and ID are thought to tautomerize their respective 
substrates to nonaromatic intermediates, but the two differ in their means of 
dehalogenation (60, 73).  TCHQ dehalogenase catalyzes dehalogenation of the TCHQ 
intermediate through nucleophilic attack on the chlorine bearing carbon by the sulfur 
of glutathione (60).  ID, on the other hand, performs nucleophilic attack on the iodine 
by the selenium of a selenocysteine (Se-Cys) (73).  Finally, both reductive 
dehalogenases reduce the covalent enzyme complex to regenerate catalytically active 
enzyme.  
The Rokita lab previously proposed a mechanism of deiodination for IYD 
based on TCHQ dehalogenase and ID mechanistic precedence (Figure 2-2) (67).  The 
initial step in the proposed mechanism of IYD catalysis involves the tautomerization 
of substrate to its keto form.  This results in the formation of an iodine bearing carbon 





step in the proposed mechanism was bolstered by inhibition of IYD activity with a 
series of N-pyridonal compounds that mimic the proposed nonaromatic intermediate 
(N-methyl derivative KI is 24 ± 8 nM) (Figure 2-3).  These derivatives displayed 
strong inhibition of deiodinase activity, which is associated with tight binding.  This 



















































































Figure 2-1. Mechanistic similarities in dehalogenation by TCHQ dehalogenase and
ID as precedence for the proposed mechanism of IYD. 
Tautomerization 
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Following tautomerization, the proposed mechanism of IYD relies on 
nucleophilic attack of the substrate’s iodine substituent by a Cys residue.   The 
nucleophilic attack of iodine by IYD is equivalent to ID catalysis although IYD was 
proposed to utilize the sulfur of an active site Cys in place of the selenium of an ID 
 
Figure 2-3. N-Pyridonal inhibitors mimic the proposed tautomeric intermediate. 
 
Figure 2-2. Proposed mechanism of IYD deiodination.  Figure modified from



















































Se-Cys.  This nucleophilic attack generates reduced tyrosine as well as an S-I 
covalent bond between a Cys residue and iodine.  As for experimental precedence, 
the thiol of Cys has been shown capable of promoting deiodination of MIT in model 
studies (74).  Additionally, deiodination of aryl iodides by thiols proceeds through a 
nucleophilic attack of iodide.   Cleavage of the C-I bond by halophilic attack from 
Cys would be facilitated by a nonaromatic keto intermediate due to reduced bond 
strength: C-I aryl bond is 65 kcal/mol while C-I allyl bond in only 41 kcal/mol (75).    
Similar dehalogenation by halophilic attack has been proposed for model studies of o-
bromophenol (76).  
The hypothesis of an active site Cys involved in catalysis was strengthened 
once the sequence of the IYD gene was identified and expressed recombinantly in 
HEK293 cells (37, 40).  Three highly conserved Cys residues were identified by 
BLAST sequence analysis of several mammals (Figure 2-4) (40).  One Cys, C13 
(Mus musculus), is located in the predicted membrane domain of IYD and not 
involved in catalysis (40).  This was confirmed as activity was retained in the 
truncated IYD variant (Δ2-32) which was present in the soluble fraction of cell 
lysates (38).  The remaining two Cys residues, C217 and C239, were located within 
the predicted catalytic domain of IYD.  Upon structural modeling with enzymes in the 
NOX/FRase superfamily, C217 and C239 (Mus musculus) were predicted to be in 
close proximity to the isoalloxazine portion of the FMN cofactor, with the sulfur of 
C239 within 5 Å (Figure 2-5) (40).  Notably, among organisms that utilize thyroxine, 




in contrast to the rest of the NOX/FRase superfamily, which lack these Cys residues 
and the ability to perform reductive dehalogenation.               
 
  
Figure 2-4. The amino acid sequence of Mus musculus IYD contains three conserved 
cysteines.  A) Sequence alignment of multiple mammalian IYD proteins according to 
Clustal W 1.83.  Sequence gaps are indicated by (.) and the consensus sequence is 
shown below the alignment.  Conserved residues are shown in red, but conserved Cys 
are shown in yellow.  Figure modified from Friedman et al. (40).  B) The conserved 
Cys in Mus musculus IYD (C13, C217, and C239) map to the transmembrane domain 
(1-24) and the NOX/FRase domain (83-285).  Figure modified from Watson et al. 






Cys was predicted to play a vital role in the mechanism of IYD and either 
C217 or C239 may function as the nucleophilic residue in deiodination.  The ability 
to express IYD in HEK293 cells provided the first possibility to selectively probe 
these two Cys residues.  Through site directed mutagenesis of IYD, C217 and C239 
were determined to be nonessential for IYD catalysis. 
Figure 2-5. Model structure of the NOX/FRase domain of Mus musculus IYD.  
Residues 88-285 of IYD were modeled using MODWEB following threading 
through NfsB-NfnB (PDB code 1ICR).  C217 and C239 are colored yellow and in 




2.2 Experimental Procedures 
Materials. Oligodeoxynucleotide primers were obtained from Integrated 
DNA Technology (Coralville, IA).  All enzymes were purchased from New England 
Biolabs (Ipswich, MA).  Na125I used for radiolabeling of DIT was obtained from 
Perkin Elmer (Waltham, MA) (78).  All other reagents were obtained at the highest 
grade available and used without further purification. 
General methods.  DNA isolation was performed using either Qiagen 
Qiaprep Mini, Midi, and Maxiprep Kits or Fermentas GeneJet Plasmid Miniprep Kit.   
PCR reactions were performed using an Eppendorf Mastercycler.  All horizontal 
DNA agarose gel electrophoresis was performed  at 125 V using the appropriate 
percentage of agarose with Fermentas Mass Mix DNA Ladder (79).  E. coli 
transformations utilized an Eppendorf Electroporator 2510 (1700 V, 1 mm gap 
cuvette) and were plated on antibiotic selective LB plates (79).  All DNA sequencing 
was performed by Geneway Research (Hayward, CA).  Protein concentrations were 
determined using the Pierce bicinchoninic acid (BCA) assay.  Vertical protein 
electrophoresis was performed at 200 V using the Bio-Rad Mini Protean 3 gel 
electrophoresis system.  Denaturing discontinuous sodium dodecyl sulfate-
polyacrylamide gel electrohphoresis (SDS-PAGE) gels (12 % acrylamide resolving 
and 5 % stacking) and 1X Laemmli running buffer were prepared according to 
standard protocols (79, 80).  Protein gels were stained with Coomassie Brilliant Blue.  
All ligations and dephosphorylations were performed under standard conditions using 




Mutagenesis of IYD.  Mutagenesis of IYD mammalian expression vector 
pcDNA3.1(+)-IYD (Dr. Jim Watson, University of Maryland) (40) containing full 
length IYD cDNA was performed according to the Stratagene Quickchange Kit.  The 
C217A mutation variant was generated with oligonucleotides 5’-CAGTGTGTCCAT 
CGCCGCAGGCCCCTGCTGGC-3’ and 5’-GCCAGCAGGAGGCCTGCGGCGAT 
GGACACACTG-3’. The C239A mutation variant was generated with 
oligonucleotides 5’-CACTACCACTCCCCTCAACGCTGGTCCTAGACTGAGGGT 
GCTCC-3’ and 5’-GGAGCACCCTCAGTCTAGGACCAGCGTTGAGGGGAGTGG 
TAGTG-3’ (mutations in bold and introduced/removed restriction sites in italics).  
The C217A/C239A double mutation variant was generated by sequential mutagenesis 
with the sets of oligonucleotides above. Quickchange reactions were digested with 
Dpn I and then transformed into One Shot Top10 E. coli (Invitrogen, Carlsbad, CA).  
DNA from colonies resistant to ampicillin was isolated by miniprep and screened for 
the C217A and C239A mutations by restriction analysis for the addition of a Stu I site 
and changes to the banding pattern by Bfa I and Hpy181 I, respectively, before the 
genes were submitted for sequencing.     
Expression of IYD in HEK293 cells. HEK293 mammalian cells were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen) 
supplemented with 10% fetal calf serum (FCS, Atlanta Biologicals) and 1% 
penicillin-streptomycinglutamine PSG (Invitrogen).  Individual constructs of IYD 
plasmids (12 μg) were incubated for 20 min with 30 µL of Lipofectamine 2000 in 
Opti-MEM (Invitrogen) and then added to cells (~90 % confluent) in 10 cm dishes. 




The cells were washed twice with 10 mL Dulbecco’s phosphate buffered saline 
(DPBS, Invitrogen) 48 hrs after transfection and finally resuspended in DPBS again. 
Cells were harvested by centrifugation (300 x g for 5 min at 4 °C).  Cell pellets were 
resuspended in 50 mM sodium phosphate pH 7.2 (1 mL/plate of harvested cells) 
supplemented with 0.25 M sucrose and 0.1 mM dithiothreitol. The cells were lysed by 
three freezing (liquid N2) and thawing (37 °C) cycles followed by three passages 
through a 20 gauge needle.   
Deiodinase activity. Enzymatic activity was measured using a standard assay 
described previously (40, 78).   Assays were typically performed by addition of 
protein preparations (100 µL) to 300 µL of Solution 2 (1.66 mM methimazole, 0.1 
mM FAD, 666 mM KCl, 333 mM potassium phosphate pH 7.4, and 166 mM 2-
mercaptoethanol), 100 μL DIT (0-50 μM), 300 μL deionized water, and 100 μL [125I]-
diiodotyrosine (D125IT) (~50 µCi/µmol).  Reactions were initiated by addition of 100 
μL of 10 % dithionite (w/v) in 5 % sodium bicarbonate (w/v).  Samples were 
incubated under ambient temperature for 30 min and quenched by addition of 100 μL 
of 0.1 % DIT (w/v) in 0.1 N NaOH.  A 250 μL aliquot (S) of the 1.1 mL final assay 
volume was removed and transferred to a vial containing 10 % acetic acid (4.75 mL) 
in order to determine the total radioactivity for each reaction sample.  The remaining 
mixture (850 μL) was then passed through a cation exchange column (3.5 mL, AG 
50W-X8 resin), washed an initial time with 10 % acetic acid (4.15 mL), and the 
eluent collected (A).  The column was then washed a second time with 10 % acetic 
acid (5.00 mL), and the eluent was again collected (B). Each sample (S, A, and B) 




and the amount of [125I]-iodide present in each sample was quantified using a Packard 
1600 TR liquid scintillation analyzer.  
The percent of iodide released from each reaction (F) was calculated using 
Equation 2-1.  The rate of iodide release (nmol/hr) was then calculated using 
Equation 2-2.  Reactions were corrected for the fraction of background radioactivity 
obtained in the absence of protein (F0), multiplied by a factor of 2 to convert the 
incubation time into hours, and then multiplied by the amount of initial substrate 
present in the assay (e. g. 10 nmol).  This number was then multiplied by a factor of 2 
because either of the iodide sites of DIT can be deiodinated, but statistically, only one 
is labeled with 125I.  Values were then normalized for the amount of IYD (µg) added 
to each reaction.  The concentration of IYD in cell lysates was estimated by 
performing densitometry measurements (ImageQuant) of crude isolates following 
electrophoretic separation and subsequent Coomassie staining (See Appendix A for a 
representative gel).  IYD turnover and kinetic constants were then calculated with 
data from multiple independent assay trials and were fit to Michaelis-Menten kinetics 
using Origin 7.0.  kcat values were obtained from the Vmax and the respective molar 


















F - F0 x x 10 nmol x 2
60 min/hr




2.3 Results and Discussion 
Investigation of cysteine involvement in IYD catalysis.  Mutation of at least 
one of the Cys residues to Ala was expected to result in inactivated enzyme.  Two 
single IYD mutation variants (C217A and C239A) and a double mutation variant 
(C217/239A) were generated in the full length Mus musculus IYD gene.  These 
variants were expressed in HEK293 cells and assayed for deiodinase activity (Table 
2-1).  The C217A variant, which was suggested to be the more distal of the Cys pair 
with respect to the flavin and active site, displayed kinetics similar to those of the 
wild-type enzyme.  Mutation of C239 resulted in a marked increase in both the 
Michaelis-Menten constant (KM) and catalytic rate (kcat) values although the kcat/KM 
decreased approximately 2.5 fold when compared to wild-type.  Lastly, the double 
mutation variant retained activity with parameters intermediate between the two 
single Cys mutation variants (38).  Thus, IYD catalysis is not dependent on the 
presence of Cys.  This may not be entirely surprising since IYD and ID belong to two 
dissimilar structural superfamilies.  What is surprising is that nature has developed 







If Cys residues are not involved in catalysis, what role could they possess?  
The Cys mutation variants were shown not to affect the NADPH activity of IYD 
which relies on a yet unidentified reductase (38).  This shows that the Cys residues 
are not critical for physiological catalysis as they are not required for dehalogenation 
of substrate or flavin reduction.  Aside from catalysis, the Cys residues could be 
structurally important and aid protein stability.  If so, they could exist as a disulfide 
bond if they truly are proximal to one another.  Even though the roles of these Cys are 
still unclear, they are certainly not involved directly in catalysis, and IYD therefore 
does not follow the precedence of dehalogenation of ID and TCHQ dehalogenase.  
The repertoire of flavin catalysis has now been expanded to include reductive 
dehalogenation in the absence of redox-active thiols.  Additional mechanisms of 
deiodination must then be investigated.   
Table 2-1. Kinetics for wild-type and IYD mutation variants.a, b 
IYD 






Wt         8 ± 3c     7.1 ± 0.9 0.89 
C217A       13 ± 4     8.3 ± 0.6 0.64 
C239A       79 ± 7      28 ± 2 0.35 
C217A C239A       42 ± 7      15 ± 2 0.36 
aValues were included in Watson et al. (38)  
bKinetic values were obtained from fitting more than 3 kinetic trials to the 
Michaelis-Menten equation using Origin 7.0 (See Appendix B).  KM, Vmax, 
and error values were obtained directly from fitting.  The kcat was obtained 
from the Vmax and the respective molar concentration of the IYD protein.   




Possible mechanisms of IYD catalysis.  Because IYD is a flavoprotein, both 
1 and 2 electron transfer mechanisms should be reexamined.  A mechanism similar to 
that already proposed would utilize a single 2 electron transfer from the reduced FMN 
(FMNred) cofactor (Figure 2-6).  This would again rely on a residue acting as a 
nucleophile and a reducing agent for deiodination.  Nucleophilic residues other than 
the most obvious Cys should be considered.  In particular, His and Lys residues could 
participate in catalysis since amines were recently shown to promote reductive 
dehalogenation in a model system (81).  Also, the intermediate which would be 
expected in the case of Lys, Lys-εNH-X, has recently been proposed for the reverse 
process involving flavin dependent chlorination (82).  Identifying residues that could 
participate as nucleophiles in IYD catalysis is problematic because the IYD gene is 
well conserved (80 % identity among mammals).  An X-ray structure of the enzyme 






















Alternative to the involvement from a nucleophilic residue, a two electron 
mechanism could proceed through hydride transfer to substrate (Figure 2-7).  Direct 
transfer of hydride from FMNred by a nucleophilic aromatic substitution (SNAr) 
mechanism is unlikely although it does provide a means of dehalogenation.  The 
electron density of the phenyl ring of the substrate makes this reaction unlikely.  
Inclusion of electron withdrawing groups like nitro substituents similar to Sanger’s 
reagent would be required for this mechanism to be considered.  However, this 
electron density problem may be overcome by tautomerization of substrate.  
Nucleophilic attack by hydride to an sp3 hybridized C but not an sp2 hybridized C 
could facilitate an SN2 like reaction and result in deiodination.  Subsequent proton 
abstraction would then generate tyrosine product.   

































Figure 2-7. Possible 2 electron deiodination mechanisms involving hydride transfer






in Chapter 1 are fundamentally different from 2 electron mechanisms because they 
involve an initial single electron transfer to substrate from FMNred to facilitate 
dehalogenation followed by an additional electron transfer from the generated flavin 
semiquione (FMNsemi).  There are two 1 electron mechanistic routes to consider 
(Figure 2-8).  The first possible route involves a free radical aromatic substitution 
(SRN1) mechanism with an initial injection of an electron into the π system of the 
substrate.  This results in a π anion radical which then facilitates deiodination, 
ultimately yielding the radical in place of the iodine.  A second addition of an electron 
and a proton would complete catalysis as tyrosine product and oxidized FMN (FMNox 
would be formed.  In contrast, the second route involves substrate tautomerization.  It 
requires an initial step involving deprotonation of the substrate phenolic hydrogen 
and protonation of the iodine bearing carbon, leading to the keto form of the 
substrate.  Addition of an electron into this system would facilitate deiodination and 
form a tyrosyl radical.  Of note, the tyrosyl radical would be capable of resonance 
stabilization due to the initial tautomerization of the substrate.  The addition of a 
second electron from the flavin semiquinone as well as reprotonation to the enol form 
of the phenol would complete catalysis by generating Tyr product.   
In order to distinguish between a 1 or 2 electron mechanism for IYD catalysis, 
the flavin derivative 5-deazaFMN can be utilized (73, 83-86).  This is due to the 5-
deazaflavin’s inability to stabilize a semiquinone radical (87, 88).  Thus, 
incorporation of 5-deazaflavin derivatives into enzymes which follow a 1 electron 
process results in loss of activity, while those which follow a 2 electron process retain 




deazaFMN, large scale isolation of recombinant IYD is required.  These topics will 





























Figure 2-8. Possible 1 electron deiodination mechanisms involving radical transfer





Chapter 3: Large scale expression and isolation of IYD 
 
3.1 Introduction 
IYD was initially characterized (31, 32) almost a decade after it was first 
isolated in low yield from bovine thyroid homogenates (35).  The purification 
procedure required solubilization of the protein by the following steps: 1) preparation 
of microsomes from thyroid tissues, 2) solubilization with steapsin, 3) fractionation 
by ammonium sulfate precipitation, and 4) sequential isolation using 
diethylaminoethyl-cellulose, hydroxylapatite, and gel filtration chromatography.  This 
lengthy purification resulted in a homogenous IYD protein which was characterized 
by molecular weight (42 kDa) (31), cofactor incorporation (FMN) (31), and reduction 
potential (-420 mV) (32).  A more thorough characterization of IYD, however, 
requires large scale isolation.  Purification from thyroid homogenates doesn’t provide 
a convenient method to accomplish this.  Thus, an alternative source for isolating 
IYD is essential.      
The gene encoding IYD was only recently identified and expressed (37, 40).  
The native IYD protein encoded by the gene was determined to be composed of three 
domains: an N-terminal membrane domain (1-24), an intermediate domain (25-82), 
and a catalytic NOX/FRase domain (83-295) (Figure 3-1) (40).  Despite the ease of 
native IYD expression in HEK293 cells, isolation would be aided by expression of a 




truncation variant IYD(ΔTM)His6 was expressed (89).  This variant lacked amino 
acids predicted to anchor IYD in the membrane and contained an additional C-
terminal polyhistidine for purification. This allowed recombinant expression of a now 
soluble and stable version of IYD.  Interestingly, further truncation of IYD to only its 
NOX/FRase domain resulted in expression of insoluble and inactive protein (89).  
This indicated that a portion of the intermediate domain is required for proper protein 
folding despite all bacterial proteins in the superfamily lacking this domain.  
IYD(ΔTM)His6 was never isolated from HEK293 cells due to the time and cost 
limitations associated with mammalian expression.  Nonetheless, mammalian 
expression allowed identification of this construct for future large scale isolation in 
other systems. 
Initially, large scale expression and isolation of IYD(ΔTM)His6 was attempted 
in E. coli by the Rokita lab.  At first, no induced protein was observed for expression 
in the BL21(DE3)pLysS E. coli strain (90).  This was attributed to codon bias since 
IYD is a mammalian protein and contains numerous codons that are infrequently used 
in E. coli genes (Codon Usage Database, Kazusa DNA Research Institute) (91).  
Figure 3-1. Engineering a soluble IYD.  An N-terminal truncation of residues 2-32






Rossetta 2(DE3) E. coli circumvented this problem because it supplements rare E. 
coli codons.  Unfortunately, the protein expressed in this strain was in the form of 
inclusion bodies (92).  Expression of insoluble protein seemed counterintuitive as 
other proteins within the NOX/FRase superfamily are bacterial and easily expressed 
by E. coli in large scale (41-44).  Attempts to aid solubilization by altering expression 
conditions (isopropyl β-D-1-thiogalactopyranoside (IPTG) 20-100 µM and 18-37 ºC) 
did not affect the expression outcome (92).  Additionally, several fusion proteins 
(glutathione-S-transferase, thioredoxin (TRX), and NusA) used to increase solubility 
did not render IYD(ΔTM)His6 soluble although the TRX fusion appeared to increase 
solubility slightly (90).  Even refolding studies with the TRX fusion protein failed to 
result in soluble protein (93).               
With bacterial expression failing to yield soluble protein, yeast and insect 
expression remained the most viable alternatives for large scale isolation of 
IYD(ΔTM)His6.  The yeast strain Pichia pastoris has garnered significant attention as 
a heterologous protein expression system over the past 15 years due to several 
attractive properties.  Namely, it provides the benefits of a eukaryotic expression 
system, it utilizes methanol for induction, and it grows to high cell densities (94).  
Expression in insect cells using baculovirus provides the most similar expression to 
mammalian cells.  This system is eukaryotic like yeast, but it has advantages in 
protein folding with machinery more similar to mammalian, protein localization (95), 
and post-translational modifications (96).   
Expression in Pichia and Sf9 insect cells were investigated simultaneously 




IYD(ΔTM)His6.  Expression in Pichia was hindered until a synthetic gene with codon 
usage optimized for Pichia was utilized.  Of the two expression systems, Sf9 cells 
provide protein with greater yields and purity.  This allowed further characterization 
of IYD(ΔTM)His6 as well as crystallographic studies which resulted in a 3-D 
structure at 2.0 Å resolution (97).    
3.2 Experimental Procedures 
Materials.  Oligodeoxynucleotide primers were obtained from Integrated 
DNA Technology (Coralville, IA).  Both EasySelect Pichia Expression and Bac-to-
Bac Baculovirus Expression Kits were obtained from Invitrogen Corporation 
(Carlsbad, CA).  All enzymes were purchased from New England Biolabs (Ipswich, 
MA).  The plasmid pcDNA3.1(+)-IYD was obtained from Dr. Jim Watson 
(University of Maryland) (40).  A synthetic variant of the Mus musculus gene flanked 
by EcoR I and Not I sites and inserted in pUCminusMCS was obtained from Blue 
Heron Biotechnology, Inc. (Bothell, WA).  All cell lines were purchased from 
Invitrogen.  Na125I used for radiolabeling of DIT was obtained from Perkin Elmer 
(Waltham, MA) (78).  Antibodies for Western blotting were obtained from Novagen-
EMD Biosciences (Madison, WI).  All other reagents were obtained at the highest 
grade available and used without further purification.  
General methods.  DNA isolation was performed using either Qiagen 
(Hilden, Germany) Qiaprep Mini Kit or Fermentas (Burlington, Canada) GeneJet 
Plasmid Miniprep Kit.   PCR reactions were performed using an Eppendorf 




was performed at 125 V using the appropriate percentage of agarose with Fermentas 
Mass Mix DNA Ladder (79).  All ligations and dephosphorylations were performed 
under standard conditions using T4 ligase, and Antarctic phosphatase, respectively.  
E. coli transformations utilized an Eppendorf Electroporator 2510 (1700 V, 1 mm gap 
cuvette) and were plated on antibiotic selective LB plates (79).  All DNA sequencing 
was performed by Geneway Research (Hayward, CA).  Pichia pastoris and 
baculovirus procedures were performed according to Invitrogen’s EasySelect Pichia 
Expression and Bac-to-Bac Baculovirus Expression Kits, respectively, unless 
otherwise noted.  Vertical protein electrophoresis was performed at 200 V using a 
Bio-Rad (Hercules, CA) Mini Protean 3 gel electrophoresis system.  Denaturing 
discontinuous SDS-PAGE gels (12 % acrylamide resolving and 5 % stacking) and 1X 
Laemmli running buffer were prepared according to standard protocols (79, 98).  
Protein gels were stained by Coomassie Brilliant Blue or used for Western Blotting.  
Electrophoretic transfer of proteins to polyvinylidene fluoride membranes 
(Invitrogen) for Western blotting was performed with the Bio-Rad Mini Trans-Blot 
Cell according to the manufacturer’s directions.  Polyhistidine tagged proteins were 
recognized using His•Tag Monoclonal Antibody and Goat Anti-Mouse IgG Alkaline 
Phosphatase Conjugate (79).  Fluorescence from ECF (GE Healthcare Bio-sciences 
Corp.-Waukesha, WI) was detected using a Storm 860 (GE Healthcare Bio-sciences 
Corp.).  UV measurements were made with a Hewlett-Packard 8453 
spectrophotometer (Palo Alto, CA) while fluorescence measurements were made with 
a Hitachi F-4500 fluorescence spectrophotometer (Tokyo, Japan).  Deiodinase 




Subcloning of IYD(ΔTM)His6 for expression in Pichia pastoris. Plasmids 
containing IYD(ΔTM)His6 were constructed for recombination into Pichia.  pPICZA-
IYD(ΔTM)His6 was generated from the Mus musculus IYD gene by PCR 
amplification of pcDNA3.1(+)-IYD (40) with primers 5’–CGGTACCTCGAGAATA 
ATGTTTGCTCAAGTTCAGCCCTGG-3’ and 5’-CTCGAGGCGGCCGCCTAATG 
GTGATGGTGATGGTGTACTGTCACCATGAT-3’.  PCR product was digested 
with Not I and Xho I and then ligated into pPICZA.  pPICZA-optIYD(ΔTM)His6 was 
assembled by inserting the synthetic variant of the Mus musculus IYD gene into 
pPICZA after EcoR I and Not I digests.  Ligated plasmids were transformed into One 
Shot Top10 cells.  Clones for both pPICZA-IYD(ΔTM)His6 and pPICZA-
optIYD(ΔTM)His6 were identified by sequencing the DNA of colonies demonstrating 
resistance to the appropriate antibiotic.  
IYD(ΔTM)His6 recombinant Pichia clones were generated for both pPICZA-
IYD(ΔTM)His6 and pPICZa-optIYD(ΔTM)His6.  Plasmids pPICZA-IYD(ΔTM)His6 
and pPICZa-optIYD(ΔTM)His6 were linearized with BstX I prior to transformation 
into electrocompetent histidine deficient GS115 Pichia pastoris cells (99).  Pichia 
colonies exhibiting zeocin resistance were analyzed for the presence of the IYD gene 
using the Easy Select Kit protocol modified to allow PCR to be performed directly 
using Pichia colonies.  These modifications entailed suspending colonies in water to 
an optical density at 600 nm (OD600) of 20, heating this by microwave on high for 1 
minute, and then directly performing PCR on the mixture in the presence of 20 μM 
primer supplied by the manufacturer.  PCR products corresponding to IYD 




the gene for IYD were analyzed for their methanol utilizing (Mut) phenotype on 
minimal methanol medium plus histidine (MMH) plates.   
Subcloning of IYD(ΔTM)His6 for expression in Sf9 insect cells.  
pFASTBAC1 plasmid containing IYD(ΔTM)His6 was constructed for bacmid 
generation.  The Mus musculus IYD gene was amplified from pcDNA3.1(+)-IYD 
(40) with primers 5’-AAGCTTAAGCTTGGATCCGCCACCATGTTTCTCCTCAC 
CCCA-3’ and 5’-CTCGAGCTCGAGCTAATGGTGATGGTGATGGTGTACTGTC 
ACCATGATC-3’ to generate the plasmid pFASTBAC1-IYD(ΔTM)His6.  The PCR 
product and pFASTBAC1 were digested with BamH I and Xho I.  The gene insert 
was ligated into the plasmid and transformed into One Shot Top10 cells.  DNA 
isolated from resistant colonies was sequenced to verify plasmid construction.  
Bacmid containing IYD(ΔTM)His6 was constructed through transposition of 
pFASTBAC1-IYD(ΔTM)His6 into the baculovirus shuttle vector, bMON14272 
(Invitrogen).  This was accomplished by transforming pFASTBAC1-IYD(ΔTM)His6 
into MAX Efficiency DH10Bac E. coli.  Colonies resistant to gentamycin, 
kanamycin, and tetracycline were then plated on bluo-gal/IPTG selective plates to 
screen for colonies containing the desired recombinant bacmid.  PCR was performed 
using DNA isolated from several white colonies to verify pFASTBAC1-
IYD(ΔTM)His6 recombination into the bacmid.  The desired bacmid was confirmed 
by sequencing PCR products.    
Recombinant baculovirus was generated with bacmid containing 
IYD(ΔTM)His6.  Serum-free adapted Sf9 cells maintained in SF-900 II SFM 




bacmid DNA and Celfectin Reagent (Invitrogen).  The IYD recombinant baculovirus 
was collected from the growth medium 72 hrs after bacmid transfection.  Virus 
concentrations were determined by an end point dilution virus titer  (100).  Virus was 
amplified with a multiplicity of infection (MOI) of 0.05 (plaque forming units 
(pfu)/cell) and the growth medium from subsequent virus propagations was saved as 
IYD recombinant baculovirus stock.   
Enzyme expression in Pichia pastoris.  Clones containing IYD(ΔTM)His6 
with a positive Mut phenotype were grown overnight in a minimal glycerol medium 
plus histidine (MGYH) to an OD600 between 2 and 6 (30 °C).  These cells were 
centrifuged (5 min at 5,000 x g) and resuspended in MMH medium for induction to 
an OD600 of 1.  Cells were then induced 48 hrs (30 °C), pelleted by centrifugation, 
and resuspended in a solution appropriate for subsequent affinity purification (500 
mM NaCl, 50 mM sodium phosphate buffer, 10 mM imidazole, 150 μM FMN, pH 
8.0). Cells were lysed by 3 passages through a French press at approximately 10,000 
psi.  Lysates were centrifuged at 12,000 x g for 10 min (4 °C) to remove cellular 
debris.  Supernatants were centrifuged a second time at 20,000 x g for 1 hr (4 °C) and 
finally filtered (0.22 μm) to remove any additional particulates.     
Enzyme expression in Sf9 insect cells.  Sf9 cells were infected by 
pFASTBAC1-IYD(ΔTM)His6 recombinant baculovirus stock in Sf9-900 II SFM with 
an MOI of 1 (pfu/cell).  Cells were incubated at 27 °C for 72 hrs and then harvested 
by centrifugation at 500 x g for 5 min (RT).  The cell pellet was resuspended in an 
appropriate solution for affinity chromatography and lysed by three freezing (liquid 




needle.  Lysates were centrifuged at 20,000 x g for 1 hour (4 °C), and finally, 
supernatant was filtered through a 0.22 μm filter. 
Purification of IYD(ΔTM)His6.  IYD(ΔTM)His6 was purified from cell 
lysates using an AKTA FPLC (GE Healthcare Bio-sciences Corp.) with a 1 mL 
HisTrap HP column chelated with Ni 2+.  Soluble lysates were applied to the affinity 
column, washed with 5 column volumes of wash buffer (500 mM NaCl, 50 mM 
sodium phosphate, 20 mM imidazole, pH 8.0) and eluted using a linear gradient of 
20-300 mM imidazole over 20 mL.    Fractions containing IYD(ΔTM)His6, as 
identified by SDS-PAGE, were pooled and dialyzed overnight (4 °C) against 10 mM 
potassium phosphate, pH 7.4.  The concentration of bound FMN cofactor was 
determined using an ε450 12,500 M
-1 cm-1 (101).  The concentration of holoenzyme 
was calculated using an ε280 of 57,600 M
-1 cm-1 determined using the Edelhoch 
method (102). 
3.3 Results and Discussion 
Expression and isolation of IYD(ΔTM)His6. The soluble IYD(ΔTM)His6 
protein identified by expression in mammalian cells (89) was investigated 
simultaneously for expression and isolation in Pichia and in Sf9 cells.  These two 
expression systems overcame the yield limitations of mammalian expression and the 




Expression and isolation of soluble IYD(ΔTM)His6 was first accomplished in 
Pichia although recombinant clones encoding the Mus musculus gene for 
IYD(ΔTM)His6 (Figure 3-2) failed to express the protein.  Cell lysates lacked 
deiodinase activity and expression of the protein was undetectable by Coomassie 
Figure 3-2. Nucleotide sequences used for expression of IYD(ΔTM)His6.  The wild-
type Mus musculus gene shown below the amino acid sequence was used for
expression in Sf9 cells, but failed to express in Pichia.  The synthetic gene used for
expression in Pichia contained numerous codon changes which are shown below the
nucleotide sequence.  Red and blue codons signify changes to bring Pichia usage




staining or by Western blotting.  Varied lengths of expression (24-96 hrs) and 
methanol induction concentrations (0.5 - 2.0 % v/v) were ineffective in stimulating 
IYD(ΔTM)His6 expression.  This absence of expression was not a result of problems 
in transformation.  PCR and sequencing verified that the desired gene had 
recombined into the Pichia genome (Figure 3-3).  It was hypothesized that the 
deficiency in expression was due to the differing codon usage between Pichia and 
Mus musculus.  The gene contains a significant number of codons rarely utilized in 
Pichia (Codon Usage Database, Kazusa DNA Research Institute) (91).   
To avoid these rarely used tRNAs, a synthetic gene was constructed (Figure 3-
2). Rare codons with usage below 5 per thousand comprised 2 % of the Mus musculus 
gene.  These codons were replaced in the synthetic gene with codons of high usage in 
Pichia.  This gene was also designed to reduce the usage of less rare codons with 
Figure 3-3. PCR verification of IYD recombination into Pichia pastoris (GS115)
clones.  Direct colony PCR was performed on a Pichia negative control which lacks
IYD gene recombination (Lane 1), a pPICZA-IYD(ΔTM)His6 Pichia clone (lane 2),
and a pPICZA-optIYD(ΔTM)His6 Pichia clone (lane 3). The AOX1 gene (2.2 kb) of
GS115 Pichia is evident in each PCR sample, confirming each clone is Mut+.  PCR
products were detected with ethidium staining following agarose (1%) gel




frequencies between 5 and 10 per thousand from 13 % to 5 %.  The synthetic gene 
also minimized repetitive usage of particular codons.  For instance, GAG which 
encodes Glu is utilized 6 times in the span of 11 codons (amino acids 27-37) in the 
Mus musculus gene.  This was reduced to two occurrences in that same span in the 
synthetic gene by substituting 4 of the GAG codons with GAA.  Finally, additional 
codon substitutions reduced the predicted mRNA secondary structure of the native 
gene transcript by approximately 46 % according to mFold (103).  Of note, a potential 
hairpin structure in the yeast consensus sequence (comparable to a Kozak sequence) 
which includes the start codon was removed.  Removal of similar mRNA secondary 
structure in this region has been shown to increase translation in E. coli (104).  
Pichia clones containing the synthetic gene now express IYD(ΔTM)His6, 
although it is at a low level (approximately 2 % of the total protein) (Figure 3-4).  
This low expression still yields IYD(ΔTM)His6 at mg quantities per L of culture 
(Table 3-1).  This is primarily because of Pichia’s ability to grow to high cell 
densities.  Purification from expression lysates required only a single Ni2+ affinity 
chromatography step and resulted in protein of acceptable purity. 
    IYD(ΔTM)His6 is also expressed very efficiently in Sf9 cells.  Sf9 cells 
infected with recombinant baculovirus containing the truncated Mus musculus gene 
resulted in very high expression with  IYD(ΔTM)His6 comprising 10 % of the total 
protein (Figure 3-4).  Isolation of IYD(ΔTM)His6 from cell lysates again required 
only a single Ni2+ affinity chromatography step but yielded an approximate 20 fold 






isolated protein was of exceptional purity (Table 3-1).  These drastic differences in 
both yield and purity outweigh the fact that expression in insect cells is more costly 
than yeast and that generating virus for infection of Sf9 cells is lengthy.  The Sf9 
system was the source of most enzyme used for characterization because of its high 
purity. 




IYD mg / g cell 
pellet 
IYD mg / L 
culture 
IYD Purityb      
( % )   
P.  pastoris 0.18 ± 0.03 2.2 ± 0.6 91 ± 5 
Sf9 3.98 ± 0.03 43 ± 8 99 ± 0.1 
aAll measurements were performed in triplicate.   
bPurity was calculated by densitometry over the full land length and 
width using ImageQuant 5.2 (See Appendix C for a representative gel).    
 
Figure 3-4. Denaturing PAGE analysis of IYD(ΔTM)His6 expression and
purification from Pichia and Sf9.  Ni2+ affinity chromatography with expression
lystates (Pichia and Sf9-lanes 1 and 3, respectively) yielded pure protein from Pichia




Characterization of isolated IYD(ΔTM)His6.  Isolated IYD(ΔTM)His6 was 
initially analyzed spectrophotometrically (Figure 3-5).  It had absorbance peaks of 
274, 363, and 447 nm.  The two higher wavelength peaks are representative of an 
oxidized flavin and are similar to those previously reported for IYD isolated from 
bovine thyroids (31).  Additionally, the 363 and 447 nm peaks are blue shifted 9 and 
3 nm, respectively, from unbound FMN.  Excitation of the IYD(ΔTM)His6 FMN at 
447 nm results in a broad fluorescence peak with a maximum emission at 527 nm.  
The intensity of this peak is reduced approximately 1.5 fold compared to free FMN.  
 
Figure 3-5. Spectroscopic analysis of IYD(ΔTM)His6.  Absorbance spectrum (10 
µM) is shown in red and emission spectrum (15 μM) following excitation at 447 nm 




In order to determine the concentration of IYD(ΔTM)His6 in solution, an 
extinction coefficient at 280 nm (ε280) was determined by the Edelhoch method (102).  
This was calculated using the extinction coefficient values for Trp and Tyr in 6 M 
guanadinium hydrochloride (GdnHCl) and 8 M urea (105).  The absorbance of 
IYD(ΔTM)His6 denatured in 6 M GdnHCl and 8 M urea was corrected for FMN 
contribution at A280.  The remaining absorbance was attributed to the five Trp and 
seven Tyr residues of IYD(ΔTM)His6.  The ε280 for the IYD(ΔTM)His6 holoenzyme 
was estimated to be 57,600 M-1 cm-1 and is almost identical to the predicted value of 
57,555 M-1 cm-1  (105).   
Based on the ε280 of IYD(ΔTM)His6, the stoichiometry of FMN in the protein 
was determined to be 2.0 FMN molecules per IYD(ΔTM)His6 dimer using the FMN 
ε450.  This ratio of FMN to protein dimer was obtained for protein isolated from both 
Pichia and Sf9 cells.  Interestingly, this stoichiometry contrasts the IYD isolated by 




Table 3-2. Kinetic parameters of IYD derivatives.a,b  
Expression 
System 







HEK293a     IYD(ΔTM) 6 ± 2     5.8 ± 0.6 0.95 
       Pichiab IYD(ΔTM)His6 19 ± 3      6.9 ± 1.3 0.36 
         Sf9b IYD(ΔTM)His6 9 ± 1      4.5 ± 0.7 0.49 
aValues are from Watson et. al using whole cell lysates of HEK293 (38).   
bKinetic values were obtained from deiodination data fit to Michaelis-Menten 
kinetics (See Appendix D).   




with IYD isolated from bovine thyroids.  The basis of this discrepancy is unclear, but 
it may due to the excess FMN added during the Ni2+ affinity chromatography step.    
The kinetic constants for deiodination of IYD(ΔTM)His6 isolated from Pichia 
and Sf9 was comparable and similar to those reported for the expression of soluble 
IYD(ΔTM) in HEK293 lysates (Table 3-2 ) (38).  The Michaelis constant KM was 
approximately three fold greater for the Pichia isolate than other proteins.  The kcat of 
all three proteins was indistinguishable since all agreed within error, while the overall 
kcat/KM was 2 fold lower for each of the isolated proteins than IYD(ΔTM) from 
HEK293 lysates.  
Structure of IYD(ΔTM)His6.  The structure of IYD(ΔTM)His6, as well as its 
costructures with substrates MIT and DIT were solved at 2.0, 2.45, and 2.6 Å (protein 
data bank codes 3GB5, 3GFD, and 3GH8), respectively, by Seth Thomas through 
collaboration with the LaRonde-LeBlanc lab (University of Maryland) (Figure 3-6) 
(97).  The structure displays electron density beginning with residue S66 of the 
interdomain, with the N-terminal portion of the protein (residues 33-65) which 
immediately follow IYD’s membrane anchor lacking density.  Additionally, IYD’s 
placement in the NOX/FRase structural superfamily was confirmed as it contains the 
α-β fold characteristic to all superfamily proteins.    The IYD structure contains 2 
FMN molecules per constitutive dimer with the active sites comprised of regions of 
each polypeptide, which is also common to the superfamily.  Additionally, most 
flavin contacts to the isoalloxazine ring, ribityl tail, and phosphate are also conserved 




   
Figure 3-6. IYD structure.  A) Native IYD homodimer structure crystallized in the 
absence of substrate.  Monomer units are distinguished by color.  Disordered regions 
are not shown and residues 156 - 177 and 195 – 208 connect the structure at 
nonterminal ends.  B) Native IYD homodimer structure crystallized in the presence 
of MIT. The substrate induced structure is shown in color according to the respective 




Interestingly, substrate binding induces helix-loop and helix formation of two 
otherwise unstructured regions (Figure 3-8).  The structure of this induced region is 
very similar to IYD’s closest structural neighbor BluB.  This is despite the low 
identity (19 %) between the two proteins and BluB’s distinctive activity of 
cannibalizing its FMN cofactor (Figure 3-9) (106).  This region of their structures
Figure 3-7. Polar contacts of A) IYD, B) BluB, and C) FRP to respective bound
FMN cofactor.  Residues making contacts are within 4 Å and correspond to
structures 3GDF, 2ISJ, and 2BKJ, respectively.  Figure was modified from Thomas




Figure 3-8. Surface properties of A) IYD and B) its complex with MIT.  Surface 
properties were calculated in PyMOL using vacuum electrostatics (110).  Blue 
indicates positive charge and red indicates negative charge.  Figure is modified from 




Figure 3-8. Surface properties of A) IYD and B) its complex with MIT.  Surface 
properties were calculated in PyMOL using vacuum electrostatics (110).  Blue 
i icates siti e c ar e a  re  i icates e ati e c ar e.  i re is ifie  fr  




differentiates IYD and BluB from the two current NOX/FRase subfamilies which 
contain similar loops at the active site but on the opposite polypeptide chain (107, 
108).  This has led to the proposal of a new subfamily belonging to both IYD and 
BluB.  IYD’s induced structure acts as an active site lid, sequestering substrate from 
solvent.  It is stabilized through polar interactions between Tyr 157, Glu 153, and Lys 
178 and the zwitterion of the substrate, which is in turn anchored by interactions to 
the isoalloxazine of the FMN cofactor.  These contacts to the zwitterion of substrate 
are unique in the NOX/FRase superfamily (41, 42, 44, 80, 106-109) and likely 
Figure 3-9. IYD structural overlay with BluB.  Structural differences between
IYD•MIT (grey) and BluB (blue) are highlighted with cartoon representation near
the active sites.  IYD induced structure is colored according to respective monomer




influence the redox properties of the FMN cofactor.  Additionally, the active site lid 
likely precludes thyroxine from binding in a productive orientation due to steric 
effects.  IYD’s ability to discern between substrate and T4 is essential for iodide 
salvage as deiodination of T4 is a futile process.  The contacts made to the zwitterion 
of substrate, as well as contacts to the substrates’ hydroxyl substituent from N10 of 
the isoalloxazine ring, the 2-hydroxy of the ribityl tail, and Ala 126 position the 
substrate almost parallel to the isoalloxazine ring of the FMN cofactor.        
 The Mus musculus and Homo sapiens IYD genes have high identity (91 %), 
and thus, the recently identified human IYD mutations (28, 29) can be rationalized 
with the reported structure (Figure 3-10).  These congenital mutations were identified 
in patients deficient in retaining thyroidal iodide which resulted in goiter and in some 
cases, developmental impairment.  Mutations equivalent to R97W and the combined 
I102L and F101 deletion in the Mus musculus gene affect the FMN binding. These 
mutations were the most severe of those identified as only minimal deiodinase 
activity was retained in each mutant (28).  This was due in particular to disruption of 
FMN contacts.  Arg 97 makes direct contact the phosphate of FMN and residues 101 
and 102 are critical for properly orienting Arg 100 near the N1 position of the 
isoalloxazine ring.  The human mutations corresponding to I112T and A216T were 
indicated to destabilize protein stability, leading to premature degradation (28, 29).  
These mutations appear to affect secondary structure and dimerization, respectively, 





  The structure of IYD(ΔTM)His6 provides a molecular basis for understanding 
mutations affecting the physiological capability of IYD to salvage iodide.  The crystal 
structure along with additional characterization studies were enabled by heterologous 
expression and isolation of IYD(ΔTM)His6.  With initial characterization complete, 
the plentiful supply of protein now allows many new investigations of IYD.  
Figure 3-10. Mapping of IYD mutations.  Residues of the Mus musculus gene
corresponding to clinically identified IYD mutations in the Homo sapiens gene are
shown in red.  Residue Arg 100 highlighted in grey is not a site associated with
direct mutation, but its polar interactions are affected by the combined I102L and
F101 deletion mutation.  IYD monomer units are colored accordingly. Figure




Chapter 4: Ligand and substrate requirements for 
recognition and catalysis by IYD  
 
4.1 Introduction 
The co-crystal structure of IYD (97) and previous reversible inhibition 
experiments (71, 72) illustrate IYD’s high turnover selectivity.  This is evident as 
IYD seems unable to tolerate modifications at the zwitterion and phenolic 
functionalities of substrate (71, 72).  The structure of IYD indicates that this is likely 
due to the polar contacts made by these functionalities to both protein residues and 
the FMN cofactor (Figure 4-1).  In fact, these polar contacts orient the substrate’s 3-
position substituent directly above the FMN isoalloxazine (Figure 4-2) (97).  In 
contrast to the zwitterion and phenolic functionalities of substrate, the role of the 3-
position substituent in substrate specificity was ambiguous following reversible 
inhibition studies.  This is because there was no clear correlation between IYD 
affinity and the electronics or sterics of 3-position substituents (71, 72, 111, 112).  
The reason for this is as much unknown as whether these tyrosine derivatives actually 
serve as substrates for IYD.   
The structure of IYD with substrate indicates that the formation of IYD’s 
active site lid confers the substrate specificity associated with the zwitterion of 
substrate (97).  Seven residues (Glu 153, Tyr 167, Trp 166, Leu 169, Thr 174, Asn 
175, and Lys 178) comprising the lid are in close proximity of the substrate (within 4 




zwitterion (Figure 4-1).  Additionally, the isoalloxazine of FMN makes polar contacts 
the zwitterion of substrate.  These zwitterion contacts secure the active site lid once 
substrate is bound by acting as a bridge between the lid and the FMN cofactor.  The 
loss of deiodinase inhibition upon modification to either the amine or carboxy of the 
zwitterion is consistent with the zwitterion contacts conferring specificity (71).  The 
phenol displays similar specificity as methylation completely abolishes any 
deiodinase activity inhibition (71).  This specificity likely results from polar contacts 
to the N10 of the isoalloxazine ring of FMN, the 2-hydroxy of the FMN ribityl tail, 
and the backbone nitrogen of Ala 126.   
Figure 4-1. MIT substrate interactions with IYD and FMN.  Polar contacts within 4
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Figure 4-3. Active site binding pockets of IYD co-crystals.  A) Surface properties
for the IYD•MIT co-crystal active site as calculated using vacuum electrostatics in
PyMOL (110). Blue indicates positive charge and red indicates negative charge.  B)
Active site alignment of IYD co-crsytal with MIT in orange and DIT in cyan.  Figure




position substituent, as well as the relatively nonpolar pocket surrounding the 3-
position supports the previous Tyr derivative inhibition data which indicates that IYD 
binds Tyr derivatives with varying electronic and steric characteristics.  Although the 
role of the substituent at the 3-position is unclear, it is important to determine if IYD 
has substrate specificity associated with the 3-position substituent since it is directly 
involved in catalysis. 
The only substituent requirements for IYD ligand recognition described to 
date were based upon inhibition of catalysis (71, 72).  In fact, there is no ligand 
recognition data for MIT and DIT beyond their respective KM values.  This is because 
ligand binding has not been directly measured until now.  A fluorescence quenching 
assay is reported here for investigating ligand specificity (115).  The assay utilizes the 
intrinsic fluorescence of oxidized FMN and the quenching observed upon ligand 
binding.  Since no reductant is present, reversible binding of MIT and DIT to IYD 
can be measured.  This assay allowed the ligand requirements for substituents at the 
3-position to be probed with a number of Tyr derivatives (Figure 4-4 and Table 4-1).  
Additionally, ligands identified by the above fluorescence quenching assay 
have been probed as substrates for IYD catalysis.  Previously, IYD activity assays 
were limited to the standard assay which detects dehalogenation via release of 125I-.  
An anaerobic assay was developed to monitor single turnover of IYD by 
spectrophotometrically observing reduction of the protein’s FMN by dithionite and 
subsequent discharge of those electrons from FMNred to substrate (115).  This assay 
alleviates the limitation of substrate 125I radiolabeling, allowing compounds to be 




expanded the list of IYD substrates to include 3-bromo, and 3-chlorotyrosine (MBT 





Figure 4-4. 3-Dimensional model of Tyr derivatives.  Structures were generated in
PyMOL (110) from coordinates of Tyr derivatives from Chem 3D 10.0.  The Tyr
derivative coordinates were energy minimums as determined by MM2 force feild
calculations by Chem 3D 10.0.  The spheres represents the Van der Waals radius of




4.2 Experimental Procedures 
Materials.   Methyl tyrosine (Me-Tyr) was obtained from Dr. Jessica 
Friedman (University of Maryland) and 3-(N-ethyl-2-pyridon-5-yl)alanine was 
obtained from Dr. Munetaka Kunishima (University of Maryland).  All other reagents 
were obtained at the highest grade available and used without further purification. 
General methods.  IYD(ΔTM)His6 was expressed and isolated from Sf9 cells 
according the method described in Chapter 3 (97).  Protein concentration was 
determined using an ε280 of 57,600 M
-1 cm-1 while an ε450 12,500 M
-1 cm-1 (101) was 
used to determine FMN concentration.  IYD(ΔTM)His6 isolated from Sf9 cells 
contained 2 bound FMN molecules per enzyme dimer.  UV measurements were made 
with a Hewlett-Packard 8453 spectrophotometer (Palo Alto, CA) while fluorescence 
measurements were made with a Hitachi F-4500 fluorescence spectrophotometer 
(Tokyo, Japan).  Analytical HPLC was performed on a JASCO PU-908/MD1510 
diode array instrument (Tokyo, Japan). 
Equilibrium binding measurements.  Ligand binding assays were 
performed by monitoring IYD solutions (1.5 μM protein, 100 mM potassium 
phosphate, pH 7.4) for a change in FMN fluorescence using an excitation wavelength 
of 450 nm and an emission wavelength of 527 nm (25 °C with stirring).  The enzyme 
solution was equilibrated 30 min prior to fluorescence analysis.  Binding of Tyr 
derivatives was monitored over a range of 4 log units centered at the concentration 
which yields 50 % quenching of fluorescence (0.015 to 415 μM depending on the 




Fluorescence intensities were corrected for minimal dilution resulting from ligand 
addition and then normalized by dividing the observed fluorescence by the initial 
fluorescence (F0) and plotted against ligand concentration [S].  Dissociation constants 
(KD) were calculated according to literature and derive from best fit to Equation 4-1 
(Tyr and Me-Tyr) and to Equation 4-2 (MIT, DIT, MBT, MCT, 3-fluoro and 3-
nitrotyrosine (MFT and MNT, respectively)) (61) as calculated by Origin 7.0.  Tyr 
and Me-Tyr were fit to Equation 4-1 because their calculated KD was 5 fold greater 
than enzyme concentration used in the assay. The remaining Tyr derivatives were fit 
to the Equation 4-2, which is a quadratic binding equation that accounts for enzyme 
concentration.  Fitting to this equation was required because the calculated KD values 
for these Tyr derivatives were less than 5 times the enzyme concentration used in the 
assay.  Fitting data to this equation, however, is associated with an increased error in 
the calculated KD values because of the tight binding curves.                          
 
Equation 4-1.       
F = F0 +F[S]0/([S]0 + KD)
 
 
   
Equation 4-2.    
F = F0 +F x









 Single turnover of IYD under anaerobic conditions.  The procedures for 
reduction and discharge of electrons from the FMN cofactor of IYD was adapted 
from Goswami and Rosenberg (32).  IYD solutions (36 μM protein unless otherwise 
noted, 100 mM potassium phosphate, pH 7.4) made anaerobic by purging the head 
space of a sealed air tight cuvette using ultra-pure nitrogen at 4 °C for 6 hrs with 
stirring.  The solution was purged an additional 1 hr at 25 °C with stirring, and these 
conditions were maintained throughout the rest of the assay.  Reduction of IYD’s 
FMN cofactor was performed by addition of anaerobic dithionite solution (~10 mM) 
until the A450 failed to decrease and the A317 (isobestic point of reduced and oxidized 
IYD) increased.  A minimum of excess dithionite (5 %) was added to ensure 
complete reduction of the cofactor.  Anaerobic solutions of Tyr derivatives (10 mM) 
were added to the reduced IYD solution in 0.333 molar equivalent additions.  The 
assay mix was monitored spectrophotometrically for 15 min after each addition.  A 
total of 2.0 molar equivalents of the respective Tyr derivative was added before the 
assay was stopped.    
HPLC analysis of products formed by anaerobic single turnover of IYD.  
IYD was removed from anaerobic single turnover samples using a 10 kDa centrifugal 
membrane filter.  These solutions were then run on a reverse phase C-18 analytical 
column (Varian, Microsorb-MV 300, 5 μm particle size, 250 mm, 4.6 mm) with a 
flow rate of 1 mL min-1 using the following method: 5 min 0 % B, 30 min linear 
gradient to 83 % B, and 10 min wash with 100 % B (Buffer A-10 mM TEAA pH 
5.5/Buffer B-methanol with 10 mM TEAA pH 5.5).  Aliquots (100 µL) of anaerobic 




times by HPLC.  Solutions of Tyr standards (36 µM) were analyzed under identical 
conditions.  The integrated signal of standards at 280 nm was used in order to 
quantitate the amount of Tyr product generated with each derivative. 
4.3 Results and Discussion 
Tyrosine substituent requirements for ligand binding to IYD.  The binding 
of MIT and DIT substrates as well as Tyr was initially investigated using the newly 
developed fluorescence quenching assay.  MIT and DIT both bind tightly to IYD, but 
there is an approximate 5 fold increase in KD when DIT binding is compared to MIT 
(Table 4-1) (115).  Clearly, the 5-position of Tyr affects binding of substrate, 
especially the addition of a large bulky group like iodine.  This significant increase in 
KD for DIT binding is likely because IYD must accommodate the bulky iodine, 
although this occurs with only slight perturbations of Leu 169, Thr 174 and Leu 172 
in the active site according to the structure of IYD (97).  This indicates that a 
substituent at the 5-position does not significantly impede ligand recognition.   
The difference in binding between MIT and DIT is minor when MIT binding 
is compared Tyr, as the KD of Tyr increases several orders of magnitude in 
comparison to MIT.  This disparity in binding would likely be even greater except a 
full binding curve for Tyr could not be obtained due to its poor solubility (115).  
Thus, the reported KD of Tyr is only a lower estimate.  IYD’s weak affinity for Tyr 
versus MIT suggests that the presence of the iodine substituent is important for ligand 





Table 4-1. Tyrosine derivative characteristics and IYD affinity. 






of free atom  
(Pauling units) 





Tyr 7.25 2.2 10.1 >1,400 
DIT 41.6b 2.7 6.35 0.47 ± 0.06 
MIT 41.6b 2.7 8.53 0.090 ± 0.40 
MBT 34.3 3.0 8.35 0.11 ± 0.03 
MCT 27.1 3.7 8.48 0.15 ± 0.02 
MFT 13.2 4.0 8.86 1.3 ± 0.2 
MNT   7.2 0.12 ± 0.05 
Me-Tyr 32.3  10.4 >1,500 
aSee reference (116). 
bCalculated from Van der Waals radius (71). 
cSee reference (117).  
d Dissociation constants were calculated by line of best fit to data (See Appendix 
E).  Uncertainties derive from the standard deviation from fitting three or more 
independent measurements.  The large uncertainty is associated with tight ligand 
binding which requires data be fit with a quadratic binding equation, Equation 4-2. 
 
 
binding would be catalytically unproductive.  The only difference between the two 
compounds is the presence of the bulky iodide substituent of MIT.  Addition of 1.5 
mM free iodide which displays minor fluorescence quenching does not strengthen 
Tyr binding (Appendix E).  This implies that certain steric or electronic 
characteristics of substituent at the 3-position may be necessary for tight binding to 
IYD. 
Consequently, the role of the substituent at the 3-position of Tyr was 
investigated using the Tyr derivatives MBT, MCT, MFT, and MNT.  These 




range in size from 7.25 to 41.6 Å3 and the halogen substituents range in electronics 
from 2.7 to 4.0 Pauling units (free halogen values) (Table 4-1).  Of note, the steric 
requirements investigated here are only for substituents of similar or smaller size than 
the iodine.  Despite their differences, MIT, MBT, MCT, and MNT all display similar 
binding to IYD while the KD of MFT is an order of magnitude greater (Table 4-1) 
(115).  This decreased affinity for MFT could not be directly correlated with 
fluorine’s decreased sterics compared to the other halotyrosines or its altered 
electronics.  Therefore, Me-Tyr was analyzed for binding since the methyl substituent 
of Me-Tyr is greater in size than the fluoro substituent of MFT, but lacks the 
electronic characteristics of halogens.  Me-Tyr binding to IYD was poor, similar to 
Tyr (115).  This result indicates that the sterics of the 3-position substituent do not 
govern ligand recognition, and instead, substituent electronics play a substantial role.  
Interestingly, the phenolic pKa’s of the Tyr derivatives are all similar except 
for Tyr and Me-Tyr which are approximately 2 units higher.  Tyr derivatives with 
lower pKas were previously reported to display greater inhibition of IYD activity, 
resulting in the hypothesis by Green that Tyr derivatives with lower pKa’s bind more 
tightly to IYD (72).  This hypothesis is consistent with Tyr and Me-Tyr having lower 
affinity than the other derivatives since their pKas are much higher.  The tight binding 
of MNT also supports this hypothesis because its pKa is one unit below the 
halotyrosine derivative pKas.  This is significant because despite the bulky and highly 
charged nitro substituent of MNT, it still displays binding within experimental error 
of MIT.  Therefore, a marked increase in the pKa from 8 may cause a ligand to lose 




appear to influence ligand recognition, the importance of the pKa in recognition is 
unclear.   
The structure of IYD shows that the substrate phenol makes contacts with the 
protein and with FMN.  These contacts could influence binding if they stabilize the 
deprotonated form of substrate.  Similar polar contacts to substrate in the acylCoA 
dehydrogenases appear to stabilize the enolate form of substrates (118, 119), and 
thus, precedence supports the involvement of the polar contacts made by the phenol 
of Tyr derivatives for stabilizing the deprotonated form of substrate.  
Ligand recognition by IYD appears to have distinct substituent requirements.  
First, the pKa of ligands appears to influence binding as Tyr and Me-Tyr, which have 
the highest pKas, bind poorly.  The relative pKa of Tyr derivatives is determined by 
the substituent at the 3-position.  Thus, the substituent must have the proper electronic 
characteristics for binding since steric requirements appear superfluous.  This was 
evidenced by Me-Tyr which has a substituent of greater size than MFT but binds 
orders of magnitude worse than MFT. 
Zwitterion requirement for IYD substrate recognition.  NADPH has been 
proposed not to be a substrate for IYD (36) although it is a common substrate of the 
NOX/FRase structural superfamily (41-44).  This hypothesis is based on experiments 
in which solubilization of IYD removes NADPH–responsive activity yet dithionite 
activity remains (35) and the dithionite activity observed in CHO cells which lack 
NADPH activity (38).  This has not been proven until now.  The fluorescence 
quenching assay used to measure ligand binding to IYD was used to determine that 




lack of observed fluorescence quenching by NADPH over a range of concentrations 
(0.013-124 µM) since reduction of flavins results in loss of fluorescence (Appendix 
E).  NADPH was not expected to quench fluorescence due to the likely involvement 
of a yet unidentified reductase proposed to mediate reduction of IYD by NADPH 
(36).  Further, the absence of fluorescence quenching by NADPH likely results from 
the sterics of IYD’s active site as IYD lacks the vestigial capacity to accommodate 
the full structure of NADPH beyond its nicotinic portion (97).   
Nicotinic acid was then assayed since it lacks the additional functionalities of 
NADPH and has been shown to stack above the FMN in the co-crystal of another 
NOX/FRase protein (44).  Nicotinic acid also failed to quench fluorescence (0.03-87 
µM) (Appendix E).  The lack of fluorescence quenching by nicotinic acid likely 
results from the absence of zwitterion and phenolic contacts which position ligands in 
the IYD active site.  Interestingly, 2-iodophenol binds (KD > 600 µM (Appendix E)) 
almost equivalently to Tyr and not MIT.  These results are consistent with previous 
reports (71, 72, 97) which indicate that IYD has distinct substrate specificity with 
regard to the zwitterion functionality.  
Substrate requirements for IYD catalysis.  For IYD catalysis to occur, the 
FMN cofactor of IYD must first be reduced by electrons from its in vivo reductant 
NADPH (23) or its in vitro reductant dithionite (36).  The FMNred is then utilized to 
dehalogenate MIT and DIT (31, 36) by transferring those electrons to substrate.  An 
anaerobic assay was developed to spectrophotometrically monitor both the reduction 




mechanistic implications of the assay will be discussed in greater detail in the 
following chapter.   
The assay was first utilized to monitor single turnover catalysis with MIT, and 
as expected, addition of MIT caused FMNred to reoxidize (Table 4-2, Figure 4-5, 
Appendix F).  HPLC analysis of the resulting turnover confirmed that approximately 
1 molar equivalent of Tyr is generated per mol of oxidation of FMNred (Appendix G).  
The process of reducing the FMN cofactor and discharging those electrons is catalytic 
as the process was qualitatively repeated with an additional turnover.  Ultimately, 
discharge of the reduced cofactor consistently yields an absorption spectrum with 
peaks similar to that of oxidized IYD except a new broad peak from 550 to 650 nm is 
also evident (115).  The spectrum indicates the presence of two distinct FMN species 
and will also be discussed further in Chapter 5.   
 
Table 4-2. Characteristics of 3-tyrosine derivatives and their turnover by IYD.  
 Bond Energya 
Discharge of 
Reduced IYD 







MIT 65 41 Yes 0.96 ± 0.02 
MBT 81 54 Yes 0.92 ± 0.01 
MCT 96 68 Yes 0.94 ± 0.02 
MFT 126 129b No 0.02 ± 0.03 
Tyr 111 86 No  
aBond energies were obtained from from McMillan and Golden (75). 
bEstimated using bond energy from McMillan and Golden (75) and Zavitsas et al. 
(120).  
cTyr product from anaerobic assays was quantified by HPLC for each respective 
Tyr derivative from three individual HPLC analyses per sample (See Appendix G 




  Since MBT, MCT, and MFT were all identified to be ligands for IYD, they 
were also tested as substrates for IYD catalysis.  Both MBT and MCT discharged the 
reduced FMN cofactor alike to MIT (Table 4-2 and Figure 4-6).  Both MBT and 
MCT were also dehalogenated by IYD with approximately 1 molar equivalent of Tyr 
product generated from each respective substrate.  In contrast, MFT failed to 
discharge FMNred similar to Tyr or be turned over to Tyr product.   
Figure 4-5. Absorbance spectra of the IYD anaerobic assay for reduction and
discharge of electrons from its FMN cofactor.  The oxidized FMN cofactor of IYD
(─) was fully reduced by additions of dithionite (─) (See Appendix G for reduction
titration).  Electrons were discharged from the reduced FMN cofactor upon addition
of 2 molar equivalents of I-Tyr substrate (─) (See Appendix F for oxidation




MBT had previously been reported to be both a substrate (112) and inhibitor 
of IYD (71).  In the report indicating MBT was a substrate for IYD, debromination of 
radiolabeled MBT was observed with thyroid homogenates (112).  On the other hand, 
MBT was reported to be a competitive inhibitor of IYD catalysis (71).  MCT was also 
previously reported to act as a reversible inhibitor of IYD (71, 111).  The reason for 
these discrepancies is unclear, but this report shows that both MBT and MCT act as 
substrates for IYD.   
IYD’s ability to dehalogenate MIT, MBT, but not MFT indicates that IYD 
does have substrate specificity for 3-position substituents.  In order to be 
Figure 4-6. FMN absorbance spectra following oxidation of reduced FMN by
addition of tyrosine derivatives.  The fully reduced FMN cofactor of IYD was
monitored for oxidation following addition of 2.0 molar equivalents of either MIT,




dehalogenated, these substituents must first be capable of being reductively cleaved 
and second be good leaving groups.  This leaving group ability is evident in the initial 
discharge of electrons from FMNred following substrate addition.  Iodide, bromide, 
and chloride are all good leaving groups and MIT, MBT, and MCT all displayed 
similar rates in discharge (0.70, 0.33, 0.18 sec-1, respectively) (Figure 4-7). Fluoride 
on the other hand, is not as good of a leaving group as the other halogens and FMNred 
was not discharged by MFT.  Although IYD does not possess enough reducing 
Figure 4-6. Absorbance measurements of the initial oxidation of the reduced FMN
of IYD by addition of tyrosine derivatives.  Time points for the initial oxidation of
the reduced FMN were monitored at 448 nm under anaerobic conditions.
Measurements were made following the initial addition of 0.333 molar equivalents
of Tyr derivatives MIT, MBT, MCT, and MFT.  The best fit (line) of data from a
single trial with each Tyr derivative is to a first order process using Origin 8.0.  Lines
are colored accordingly to serve a guide for oxidation of the reduced FMN by the




potential to facilitate dehalogenation of the C-F bond of MFT, clearly IYD has 
enough dehalogenating power to reductively dehalogenate both MBT and MCT. 
Conclusion.   This report definitively shows MBT and MCT serve as 
substrates for IYD.  Biologically, MBT, MCT, and MNT serve as biomarkers for 
inflammatory diseases like asthma (121), rheumatoid arthritis (122), cystic fibrosis 
(123), and even arteriosclerosis (124).  These Tyr derivatives are released upon 
proteolysis from proteins whose Tyr residues have been modified oxidatively. 
Upregulation of eosinophil peroxidase causes increased levels of hypobromous acid 
which ultimately leads to the generation of MBT (125, 126).  Upregulation of 
myeloperoxidase causes increased hypochlorous acid and reactive nitrogen species 
production which results in the generation of MCT and MNT, respectively (124, 127, 
128).  These Tyr derivatives are liberated upon proteolysis and metabolized.  
However, not all of the enzymes involved in this metabolism have been identified 
(Figure 4-8).  MNT is metabolized to 3-nitro-4-hydroxyphenylacetic acid and then 
excreted in urine (129).  This contrasts MBT and MCT which are dehalogenated to 
Tyr before being metabolized to hydroxyphenlyacetic acid and excreted (111).  The 
enzyme responsible for dehalogenating MBT and MCT is unknown.  IYD localized 
to the thyroid is unlikely to be involved in MBT and MCT dehalogenation, but IYD’s 
presence in the liver and the kidney would provide the means for such an involvement 
(27, 30, 39, 111, 130).  Thus, further investigation into IYD’s possible physiological 
role in metabolizing these derivatives is warranted.  
Because IYD is able to dehalogenate both MBT and MCT in addition to its 




Halogenated compounds and solvents are valuable industrial components, but they 
persist in the environment long after their intended use as the strength of the C-X 
bond confers much of the natural stability of halocarbons.  Although most 
microorganisms lack the enzymatic capacity to metabolize these recalcitrant 
pollutants, numerous organisms have evolved under selective pressure to degrade 
these halocarbons.  This has resulted in enzymatic bioremediation of halocarbons 
receiving significant focus (131-135) as compounds like polychlorinated biphenyls 
continue to pose an environmental problem today (136) despite decades old 
manufacturing bans.  Because IYD degrades C-Cl, C-Br, and C-I bonds, it presents a 
future bio-inspired method of degrading halogenated pollutants providing the 























Figure 4-7. Metabolism of A) MNT and B) MBT and MCT.  MBT and MCT are
first dehalogenated by an unknown enzyme before being metabolized to 4-






Chapter 5:  Investigation of a 1 versus 2 electron mechanism 




The original mechanism proposed for IYD catalysis relied on a nucleophilic 
attack of an active site cysteine on the substrate’s iodine (67).  Despite the 
mechanistic precedence illustrated by TCHQ dehalogenase (60) and ID (Chapter 1) 
(63, 64), the Cys to Ala mutation variant enzymes presented in Chapter 2 maintained 
activity and proved this mechanism incorrect (38).  The lack of Cys involvement was 
confirmed by the structure of IYD which located the Cys residues far from the active 
site of IYD (Figure 5-1) (97).  Therefore, other 1 and 2 electron transfer mechanisms 
presented in Chapter 2 must be considered for IYD catalysis since IYD definitively 
breaks from mechanistic precedence.  Although FMN supports both 1 and 2 electron 
processes, 5-deazaflavins are only capable of catalyzing 2 electron processes (87, 88).  
Consequently, reconstituting IYD with 5-deazaFMN can distinguish between possible 
1 or 2 electron processes for IYD catalysis.   
 A 2 electron mechanism similar to the Cys-based proposed mechanism (67) 
could still be possible (Figure 2-6).  This mechanism would require another residue 
replace the role of Cys as the nucleophile in the redox reaction.  His and Lys are the 
most likely residues to act as the catalytic nucleophile in this mechanism since amines 
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Still, other 2 electron processes should also be considered.  These mechanisms 
presented in Chapter 2 involve direct hydride transfer from FMNred to substrate 
(Figure 2-7).  The first of these possible mechanisms involves an SNAr hydride 
reaction at the substrate’s iodine bearing carbon.  This mechanism is highly unlikely 
in the absence of electron withdrawing groups (137), which both MIT and DIT lack.  
Instead, an alternate 2 electron mechanism involving tautomerization of substrate 
prior to hydride transfer is more likely (Figure 5-2).  This hydride transfer to an sp3 
hybridized carbon is similar to an SN2 mechanism, and dehalogenation would be 
expected.  Formation of the substrate tautomer is also consistent with the high affinity 














































 IYD catalysis via a 1 electron process should similarly be considered since 
few reductive dehalogenases being suggested to utilize 1 electron mechanisms (68, 
69).  Several IYD mechanisms involving 2 sequential 1 electron transfers to substrate 
which were presented in Chapter 2 are possible (Figure 2-8).  The first plausible 1 
electron transfer mechanism involves an SRN1 reaction in which a single electron 
from FMNred is injected into the aromatic system of substrate (Figure 5-3).  This 
could occur by either injection into the aromatic π system of substrate to generate a 
radical anion intermediate, or by injection of an electron directly at the iodine bearing 
carbon (Figure 5-4).  Both of these electron injections would lead to dehalogenation 
and generation of an intermediate with a radical in place of iodine.  The second 
addition of an electron by FMNsemi and a proton to the radical intermediate would 
then complete catalysis to Tyr.  
 
Figure 5-3. Possible SRN1 electron mechanism for IYD catalysis involving electron





















































An alternative 1 electron mechanism involving injection of an electron into a 
substrate tautomer is also possible.  This would occur by tautomerization of substrate 
to the proposed nonaromatic keto intermediate before an electron from FMNred is 
injected into the system (Figure 5-5).  The electron acceptor could be either the 
carbonyl to form a ketyl radical which labilizes the C-X, allowing for elimination of 
the halide, or the iodine bearing carbon which causes spontaneous iodide elimination 
(Figure 5-6).  Of note, both possible tautomer mechanisms would yield the same 
stable tyrosyl radical.  Catalysis would then be completed by transfer of a second 
electron from FMNsemi to the tyrosyl radical followed by reprotonation to the enol Tyr 
product.   
IYD mechanisms involving either 1 or 2 processes can be differentiated by 
incorporating modified flavin analogues into IYD.  The unnatural 5-deazaflavins are 













Figure 5-4. IYD aryl 1 electron mechanism could proceed by injection of an electron





(87, 88) but are retain the capability of catalyzing 2 electron transfers.  This is because 
the N5 position of the isoalloxazine is directly involved in stabilizing the FMNsemi 
(88).  5-deazaflavins are commonly thought to be catalytically similar to 
nicotinamides.  Therefore, these deazaflavin derivatives have been utilized to 
differentiate whether an enzyme follows a 1 or 2 electron mechanism (73, 83-86).  
































































Figure 5-5. Possible 1 electron mechanism for IYD catalysis involving electron




substituted with 5-deazaflavin, while enzymes which utilize a 2 electron process may 
retain catalytic activity with 5-deazaflavin.   
Thus, the flavin derivative 5-deazaFMN can be used to distinguish between a 
1 or 2 electron mechanism for IYD catalysis.  Flavoproteins must first have their 
native flavin cofactor removed to generate apoprotein before 5-deazaflavins can be 
incorporated into the enzymes.  Generally, the apoflavoproteins have been shown to 
readily recombine with flavin derivatives possessing modified isoalloxazine 
functionalities (138-140).  IYD apoenzyme was therefore generated and reconstituted 
with 5-deazaFMN and a control deazaflavin, 1-deazaFMN, which can participate in 
both 1 and 2 electron processes (87).  As described in this chapter, the IYD•5-
deazaFMN reconstituted holoenzyme lacked appreciable deiodinase activity while 
IYD•FMN and IYD•1-deazaFMN reconstituted holoenzymes supported catalysis, 


























Figure 5-6. IYD tautomer 1 electron mechanism could proceed by injection of an






5.2 Experimental Procedures 
Materials.  1-DeazaFAD and 5-deazaFAD were gifts from Dr. Dave Ballou 
and Dr. Bruce Palfey (University of Michigan).  All other reagents were obtained at 
the highest grade available and used without further purification. 
General methods.  IYD(ΔTM)His6 was expressed and isolated from Sf9 cells 
according the method described in Chapter 3 (97).  The protein concentration of 
isolated IYD was determined using the ε280 of 57,600 M
-1 cm-1 from Chapter 3. This 
value accounts for the A280 contribution of the 2.0 bound FMN cofactors of isolated 
IYD.   This ε280 value can only be used for IYD samples containing two bound flavin 
cofactors.  Protein concentration of reconstituted holoenzymes is described below in 
the next section.  UV measurements were made with a Hewlett-Packard 8453 
spectrophotometer (Palo Alto, CA) while fluorescence measurements were made with 
a Hitachi F-4500 fluorescence spectrophotometer (Tokyo, Japan).  Analytical HPLC 
was performed on a JASCO PU-908/MD1510 diode array instrument (Tokyo, Japan).   
Conversion of FAD analogues to FMN analogues.  FMN, 1-deazaFMN and 
5-deazaFMN were obtained from conversion of FAD, 1-deazaFAD, and 5-deazaFAD, 
respectively, using Naja naja snake venom (Sigma-Aldrich, St. Louis, MO) according 
to Chakraborty and Massey but on a 50 fold smaller scale (106).  This 
phosphodiesterase reaction was run overnight at 25 ºC and monitored for completion 
by HPLC analysis using an isocratic elution containing 20 % methanol in 10 mM 
TEAA, pH 6.0.  Upon full conversion to the respective FMN analogues, the reaction 




16,000 x g for 2 min.  The supernatants containing the respective FMN derivatives 
were removed for reconstitution of IYD apoenzyme.   
Generation of IYD apoenzyme.  IYD(ΔTM)His6 apoenzyme was generated 
using a procedure inspired by Rosenberg and Goswami (31).  Purified IYD (1 mg) 
was applied to a 1 mL HisTrap HP column chelated with Ni2+ using an AKTA FPLC 
(GE Healthcare Bio-Sciences Corp.) and washed with 5 column volumes of wash 
buffer similar to the procedure described in Chapter 3.  The FMN cofactor of isolated 
IYD(ΔTM)His6 was then removed with wash buffer supplemented with guadinium 
hydrochloride (GdnHCl).  This was performed with step washes increasing from 0.0, 
0.6, 1.05, and finally 1.5 M GdnHCl followed by decreasing GdnHCl step washes 
from 1.5, 1.05, 0.6, and finally 0.0 M.  The volume of each step wash was 3 column 
volumes except the 1.5 M GdnHCl wash which was 6 column volumes.  The flow 
rate for the procedure was 1 mL/min, although the flow rate was altered to 0.05 
mL/min for 1 min following the first and third column volume of the 1.5 M GdnHCl 
wash to remove the flavin cofactor.  Upon completion of the step washes, 
IYD(ΔTM)His6 apoenzyme was eluted from the column with wash buffer containing 
300 mM imidazole.  IYD(ΔTM)His6 apoenzyme was analyzed by UV at 280 nm and 
450 nm to determine the relative amount of generated apoenzyme and retained 
holoenzyme.    
Reconstitution of IYD apoenzyme with flavin derivatives.  IYD(ΔTM)His6 
apoenzyme was reconstituted with FMN, 1-deazaFMN, or 5-deazaFMN based on a 
procedure by Whitfield and Mayhew (141).  These FMN analogues were obtained 




venom as described above.  The respective FMN supernatants following the FAD 
digests were added directly to eluted IYD(ΔTM)His6 apoenzyme (approximately 10 
µM) for reconstitution by simply incubating with 2 eq. of the respective FMN 
derivatives at 4 ºC for 2 hrs.  These solutions (approximately 10 mL) were then 
dialyzed overnight against 100 mM potassium phosphate buffer, pH 7.4 and analyzed 
spectrophotometrically to determine protein and cofactor concentrations as described.  
Protein concentration of IYD reconstituted holoenzymes were estimated using 
UV/Vis spectroscopy and the following steps.  First, the bound cofactor concentration 
was determined using the FMN, 1-deazaFMN, and 5-deazaFMN extinction 
coefficients of ε450 12,500 M
-1 cm-1 (101), ε540 of 6,800 M
-1 cm-1 (87), and ε396 of 
12,000 M-1 cm-1, respectively (142).  Second, the A280 contribution of these FMN 
analogues was estimated based on the concentration of bound flavin.  Next, the 
remaining A280 following correction from cofactor contribution was attributed to IYD 
protein.  This absorbance was used to determine the IYD protein concentration with 
the ε280 of 45,100 M
-1 cm-1 determined by the Edelhoch method (102) for IYD protein 
in the absence of cofactor.  Now with both bound cofactor concentrations and IYD 
protein concentrations, the bound flavin ratio of cofactor molecules per IYD dimer 
was calculated.  Lastly, enzyme concentrations used in experiments were normalized 
for IYD protein containing bound cofactor in the active site since only these active 
sites would be capable of performing catalysis.   
Deiodinase activity.  IYD turnover was measured according to the procedure 
described in Chapter 2 except the assay was performed in the absence of free FAD.  




as described above.  The standard deiodinase assay was performed for IYD•FMN and 
IYD•1-deazaFMN to obtain kinetic parameters.  Additionally, turnover was measured 
at 20 µM DIT for each of the respective IYD holoenzymes.   
Equilibrium binding measurements with IYD•5-deazaFMN holoenzyme.  
Fluorescence quenching assays to measure MIT binding to IYD•5-deazaFMN 
holoenzyme were performed according the procedure described in Chapter 4.  IYD•5-
deazaFMN holoenzyme was excited at 399 nm and emission was monitored at 461 
nm.  Holoenzyme concentrations were normalized for IYD active sites containing 
cofactor as described above.    
Single turnover of IYD•deaza holoenzymes under anaerobic conditions.    
Anaerobic assays of IYD cofactor reduction and discharge of electrons were 
performed similarly to the procedure described in Chapter 4.  Holoenzyme 
concentrations were normalized for IYD active sites containing cofactor as described 
above.  The deazaFMN cofactor of IYD•5-deazaFMN (7 µM) and IYD•1-deazaFMN 
(5 µM) was reduced by serial addition of anaerobic dithionite stock solution (~10 
mM) until their oxidized cofactor absorbance maxima (540 nm and 396 nm for 1-
deazaFMN and 5-deazaFMN, respectively) failed to decease.  Anaerobic solutions of 
tyrosine derivatives (10 mM) were added to the reduced IYD solution in additions of 
1 molar equivalent each.  Additional equivalents were added simply to increase the 





HPLC analysis of products formed by anaerobic single turnover of 
IYD•deaza holoenzymes.  HPLC analysis of anaerobic assays was performed 
according to the procedure described in Chapter 4, except 500 µL rather than 100 µL 
aliquots of completed anaerobic assay solutions were analyzed.   
X-band EPR measurements.  Electron paramaganetic resonance (EPR) 
spectra were collected on a Bruker EMX 6/1 spectrometer equipped with a 
microwave frequency meter by Dr. Veronika Szalai (University of Maryland, 
Baltimore County).  IYD sample spectra were collected with the following 
experimental parameters: microwave frequency, 9.415 GHz; microwave power, 0.054 
mW; modulation amplitude, 10 G; time constant, 40.96 ms; conversion time, 81.92 
ms; gain, 1 × 104; 16 scans; temperature, 77 K.  Quantitative spectra were collected 
with the following changes in experimental parameters: microwave frequency, 9.41 
GHz; gain, 5 × 104 and 5 x 103 for IYD and TEMPO, respectively; 4 scans. IYD 
sample was prepared by concentrating the anaerobic assay sample following 
completion to 500 μM using a 10 kDa centrifugal membrane filter and then diluting 
the concentrate with 50 % glycerol.  The IYD sample was then stored 16 hrs at 4 °C 
prior to EPR measurements.   Measurements of samples were scaled for any gain and 
volume differences.  A calibration curve was generated using TEMPO (250, 100, 50, 
and 0 μM) where the double integral of sample intensity was plotted against 





5.3 Results and Discussion 
Reconstitution of IYD apoenzyme with flavin derivatives.  Before 1- and 5-
deazaFMN could be utilized to probe IYD’s mechanism, IYD’s native FMN cofactor 
was removed.  Generation of IYD apoenzyme requires strong denaturing conditions 
such as the presence of 1.5 M GdnHCl.  IYD apoenzyme was ultimately obtained 
with no detectable bound FMN according to UV/Vis spectroscopy after washing 
several minutes under these denaturing conditions (Figure 5-7).  Apoenzyme was then 
reconstituted with FMN, 1-deazaFMN, or 5-deazaFMN to yield an estimated 1.2, 0.9, 
and 1.2 cofactor molecules per IYD dimer, respectively (Figure 5-7).  These ratios are 
Figure 5-7. IYD holoenzymes reconstituted with flavin derivatives.  IYD•FMN, 1-
deazaFMN, and 5-deazaFMN holoenzymes were generated with the respective
FMN derivatives and IYD apoenzyme.  The inset graph shows the flavin absorbance




well below the 2.0 FMN cofactor molecules per IYD dimer for IYD isolated from Sf9 
expression culture.  The lack of full reconstitution in the generated holoenzymes may 
result from competition between phosphate from buffer and the flavin nucleotides 
since the site in which the phosphoester of FMN binds is critical to cofactor affinity 
(28).  There is likely some irreversible denaturation occurring during the generation 
of IYD apoenzyme since approximately 70 % of the IYD was recovered following 
reconstitution according to absorption measurements.  Nonetheless, the reconstituted 
holoenzymes allow the IYD mechanism to be probed. 
Deiodinase activity of IYD•deazaFMN holoenzymes.  Deiodinase activity 
of the reconstituted enzymes was analyzed using the standard iodide release assay.  
The resulting activity of the respective IYD holoenzymes was normalized for protein 
active sites containing flavin since only IYD active sites with bound cofactor are 
catalytically competent.  When the activity of the respective holoenzymes at 20 µM 
substrate were compared, the IYD•5-deazaFMN holoenzyme was found to possess 
minimal deiodinase activity, while both IYD•FMN and IYD•1-deazaFMN 
holoenzymes support catalysis (Table 5-1).  A difference between the deazaFMN 
holoenzymes is clearly evident as IYD•1-deazaFMN activity is 85 % of the 
IYD•FMN holoenzyme, while IYD•5-deazaFMN is only 10 % compared to 
IYD•FMN.  The IYD “apoenzyme” also displayed deiodinase activity, although low.  
This minimal activity was attributed to the lack of complete removal of FMN cofactor 
from IYD.  Interestingly, the IYD “apoenzyme” activity was greater than that of the 





Table 5-1. Kinetics of reconstituted IYD flavin holoenzymes.a  
  Kinetic parameters 
IYD holoenzyme 
Activity at 20 µM 
DIT (units µg-1)b, c 
KM         
(µM) 
kcat        
(min-1) 
kcat/KM        
(min-1 µM-1) 
Isolated IYDd Not determined 9.1 ± 1.4 4.5 ± 0.7 0.49 
IYD•FMN 1.6 ± 0.2 52 ± 8 3.5 ± 0.4 0.07 
IYD•1-deazaFMN 1.4 ± 0.2 25 ± 1 1.6 ± 0.1 0.06 
IYD•5-deazaFMN  0.2 ± 0.01 Not determined 
IYD Apoenzyme  0.2 ± 0.02 Not determined 
aMeasurements were performed in triplicate 
bOne unit µg-1 is defined as nmol of I- released per hour per µg of IYD. 
cAssays were performed with 9 µg of IYD•FMN, 11 µg of IYD•1-deazaFMN, 30 
µg of IYD•5-deazaFMN, or 50 µg of IYD apoenzyme per 1 mL reaction.  
dKinetic values are from IYD isolated from Sf9 cells reported in Chapter 3. 
 
likely results from residual apoenzyme activity and not from actual catalysis by the 
IYD•5-deazaFMN holoenzyme. 
To verify that the IYD•5-deaza holoenzyme lacks catalytic ability and not just 
affinity for substrate, a fluorescence binding assay to measure MIT affinity was 
performed.  The IYD•5-deazaFMN holoenzyme’s affinity for MIT was 2 fold less 
than the isolated IYD enzyme (190 ± 20 nM for IYD•5-deazaFMN versus 90 ± 40 
nM for MIT binding to isolated IYD (115), respectively (See Appendix E)).  This 
showed that indeed incorporation of 5-deazaFMN does not significantly affect 
substrate binding.   
Additionally, the 5-deazaFMN cofactor was also still capable of being 
reduced by dithionite because IYD activity requires a reduced cofactor.  This was 




deazaFMN cofactor was capable of being reduced anaerobically by dithionite since 
the λmax of oxidized 5-deazaFMN (396 nm) clearly decreased upon addition of 
dithionite (Figure 5-8). Monitoring the reduction of the 5-deazaFMN cofactor was 
imperative since protein interactions or lack thereof can alter the redox properties of 
bound flavins.  This is evident with IYD as FMN bound to IYD possess a 
significantly lower reduction potential than unbound FMN (-412 mV (32) versus -216 
mV (143), respectively).  Such a difference in 5-deazaFMN (-311 mV unbound) 
Figure 5-8. Absorbance spectra of the IYD•5-deazaFMN holoenzyme anaerobic
assay for reduction and discharge of electrons from its cofactor with MIT.  Additions
of dithionite to the oxidized 5-deazaFMN (─) resulted in fully reduced 5-deazaFMN
(─).  Reoxidation of 5-deazaFMN (─) was monitored upon addition of 1 molar




(143) could prevent catalysis if when bound to IYD its reduction potential were lower 
than dithionite’s (-660 mV).   
In order to further validate that the IYD•5-deazaFMN holoenzyme lacks 
catalytic ability, MIT was added to the above reduced IYD•5-deazaFMN holoenzyme 
generated by the anaerobic single turnover assay and then analyzed for deiodination.  
Interestingly, MIT addition resulted in a 35 % increase in the λmax absorbance 
compared with oxidized IYD•5-deazaFMN (Figure 5-8).  Although this increase in 
absorbance might indicate that electrons from reduced 5-deazaFMN are discharged to 
MIT, resulting in deiodination, HPLC analysis of this assay detected less than 0.05 
eq. of Tyr generated (Appendix G).  This suggests that the increase in the cofactor 
absorbance must be caused by something other than catalysis.  A change in cofactor 
absorbance could result from a change in the extinction coefficient possibly resulting 
from substrate binding since MIT stacks above the isoalloxazine of flavin, but this 
seems unlikely since the presence of MFT does not appear to affect the absorbance of 
FMNred bound to IYD.  The regain in A396 is more likely the result of slow 
reoxidation by trace molecular oxygen.  Overall, IYD•5-deazaFMN is likely 
catalytically deficient because it is capable of undergoing the initial steps of IYD 
catalysis (binding of substrate and reduction of cofactor) but lacks the ability to 
catalyze substrate turnover.      
Because IYD•5-deazaFMN holoenzyme appears catalytically deficient, the 
kinetic parameters of deiodination were calculated only for IYD•FMN and IYD•1-
deazaFMN holoenzymes. The kinetics of these two holoenzymes differ as both the 




IYD•1-deazaFMN holoenzyme (Table 5-1).  The kcat and KM differences of the two 
holoenzymes are proportional to each other such that they yield an almost identical 
kcat/KM for each.  Compared to isolated IYD, IYD•FMN retains a similar kcat, but its 
KM is increased by over 5 fold.  The IYD•1-deazaFMN holoenzyme’s kcat is almost 3 
fold lower and the KM is 2.5 fold greater compared to isolated IYD.  Also, the overall 
kcat/KM of the two reconstituted holoenzymes is several fold lower than the protein 
directly isolate form Sf9 cells.  These kinetic results for the IYD•FMN and IYD•1-
deazaFMN holoenzymes present a more accurate depiction of the activity differences 
between the two holoenzymes than the measurements at the single substrate 
concentration of 20 µM described previously.  This is because their activities at 20 
µM are not at their respective maximum catalytic rates, and hence, their activities 
appear far more similar at 20 µM substrate. 
The reason for the 2 fold difference in kinetic parameters of IYD•FMN and 
IYD•1-deazaFMN is unclear since both likely perform catalysis in a 1 electron 
fashion.  IYD’s reduction potential is approximately 200 mV lower than free FMN (-
216 mV (143)).  Although free 1-deazaFMN has a lower redox potential (-280 mV 
(143)) than free FMN, its unknown whether binding to IYD would cause a similar 
decrease in the reduction potential for bound 1-deazaFMN.  It is possible that 1-
deazaFMN could disrupt the involvement of Arg 100 in catalysis since Arg 100 is 
positioned at the N1 of the isoalloxazine and likely stabilizes the reduced flavin 
(Figure 5-9).  The use of 1-deazaFMN with a carbon at the N1 position could obstruct 




IYD•1-deazaFMN is catalytically less efficient than IYD•FMN and may result 
from a loss of IYD’s reducing power.  This possibility was investigated with the 
turnover of MCT since its aryl C-X bond strength is approximately 30 kcal/mol 
greater than MIT (Table 4-2).  IYD•1-deazaFMN holoenzyme did have enough 
reducing power to discharge electrons from the reduced cofactor to MCT (Figure 5-
10).  Also, HPLC analysis of the assay confirmed dehalogenation of MCT as 0.75 eq. 
of Tyr were generated (Appendix G).  This process was lengthy as addition of 6 
equivalents of MCT over 1.5 hrs still did not fully discharge the reduced cofactor.  In 
fact, full oxidation of the cofactor required the system be aerobic for almost 1.5 
additional hrs.  This contrasts IYD•FMN which undergoes complete oxidation 
Figure 5-9. The N1 and N5 of the isoalloxazine of FMN are positioned for catalytic
involvement of residues.  Thr 235 makes a polar contact (represented by the blue
dash) to the N5 of the isoalloxazine of FMN.  Arg 100 is positioned to stabilize the




approximately 6 fold faster.  Because IYD•1-deazaFMN holoenzyme does possess 
enough reducing power to dehalogenate MCT, the basis for the kinetic discrepancy 
between the IYD•FMN and IYD•1-deazaFMN holoenzymes remains unclear.       
IYD catalysis likely follows a 1 electron mechanism of dehalogenation.  
The activity of the 1- and 5-deazaflavin holoenzymes indicate that IYD performs 
catalysis using a 1 electron mechanism.  If this indication is accurate, IYD likely 
stabilizes an FMNsemi.  Goswami and Rosenberg reported the generation of a broad 
absorbance with a maximum of 585 nm during the reduction of IYD with 0.5 
Figure 5-10. Absorbance spectra of the IYD•1-deazaFMN holoenzyme anaerobic
assay for reduction and discharge of electrons from its cofactor with MCT.
Additions of dithionite to the oxidized 1-deazaFMN (─) resulted in fully reduced 1-
deazaFMN (─).  Reoxidation of 1-deazaFMN by MCT (─) (6 molar equivalents)
was monitored for 1.5 hrs.  Complete reoxidation of 1-deazaFMN (─) by aerobic




equivalents of dithionite (32).  This absorbance then decreased as the enzyme 
approached full reduction and was attributed to a neutral FMNsemi radical because 
these flavin species generally have a broad absorbance from 500-700 nm (46).  
Interestingly, this species was never observed in the reduction of isolated IYD 
reported here despite the use of identical conditions (Appendix F).  However, a 
similar species was observed during the anaerobic discharge of electrons from 
FMNred by MIT, MBT, MCT, and MNT. 
Two distinct FMN species appear within IYD after single turnover (Appendix 
F).  The characteristic FMNox species is not fully regenerated during the discharge 
and an additional broad absorbance similar to that observed by Goswami and 
Rosenberg (32) is generated around 600 nm.  Because the FMN species’ broad 
absorbance spans the same wavelengths (500-700 nm) as characteristic neutral 
FMNsemi radicals, a discharged IYD sample was analyzed by EPR.  X-band EPR 
measurements confirmed the presence of a radical with a g-factor of 2.0027 and a line 
width of 20.3 G (Figure 5-11).  These EPR features indicate that the radical is likely a 
neutral flavin semiquinone since these radicals have a line width of 20 G and anionic 
flavin radicals have a characteristic line width of 15 G (144).  It was considered that 
the broad 600 nm peak and radical could result from the presence of either an active 
site Trp or catalytic intermediate tyrosyl radical, but neither of these possibilities 
seem likely as tyrosyl radicals have a g-factor of 2.004 and a λmax at 412 nm (145-
147), while Trp radicals have a line width of 18 G and λmax at 512 nm and 536 (145, 





The radical species of IYD possesses unusual stability.  When stored under 
aerobic conditions at 4 ºC following completion of the anaerobic single turnover 
assay, the broad 600 nm absorbance peak associated with the radical is stable for 
several days.  Interestingly, this neutral semiquinone radical comprises only 8 % of 
the total FMN.  The reason for this low concentration is unclear, but this species 
appears to be a catalytically unproductive trap.  Anaerobic reduction of the FMNsemi 
species which is generated following a single turnover with MIT only occurs after the 
FMNox species is fully reduced.    
Figure 5-11. EPR spectrum of IYD following anaerobic assay for reduction and
discharge electrons from FMN.  X-band EPR measurements were made with an IYD
sample (250 μM) stored 16 hours at 4 °C under aerobic conditions following




This radical species is evident after discharge of electrons from FMNred by 
addition of MIT, MBT, MCT, and MNT.  However, discharge by MNT generates 
approximately 2 fold more of the radical species than the other derivatives based on 
their absorbencies at 585 nm (Figure 5-12).  The 448 nm peak associated with FMNox 
could not be used to confirm the difference in the amount of FMNsemi generated 
between MNT and the halotyrosines because of the A448 contribution of MNT.    
Unlike the halotyrosines which discharged the FMNred, there was a lack of reactivity 
with MNT.  HPLC analysis of the completed MNT assay yielded a single peak with a 
retention time identical to MNT standard and less than 0.05 eq. of Tyr generated.  It is 
Figure 5-12. FMN absorbance spectra following oxidation of reduced FMN by 
addition of MIT or MNT derivatives.  The fully reduced FMN cofactor of IYD was 




possible that discharge of electrons from the FMNred to MNT could occur in a radical 
fashion without elimination of the nitro substituent.  This would result in an MNT 
anion radical species which could be readily reoxidized by oxygen when the solution 
became aerobic following the assay.  A similar process occurs in the reduction of 
nitroaromatic compounds by a number of oxygen sensitive nitroreductases (150-155).  
Ironically, nitroreductases from the NOX/FRase superfamily are all oxygen 
insensitive and perform catalysis in an obligate 2 electron fashion (80, 109).   
 The contrasting ability of IYD to promote 1 electron chemistry is also 
supported by the hydrogen bond interaction between the side chain-OH of Thr 235 
and the N5 position of isoalloxazine (Figure 5-9) (97).  This is unusual for 
flavoproteins as hydrogen bond contacts to the N5 position usually consist of 
backbone or side chain-NH interactions (47), as seen with backbone interactions of 
the NOX/FRase superfamily proteins.  Side chain contacts to the N5 similar to IYD 
are predicted to aid stabilization of anionic semiquinone radicals in a family of 
electron transfer flavoproteins (156).  Additionally, BluB, which is the only other 
protein in the same subclass as IYD within the NOX/FRase superfamily, contains a 
similar contact between the side chain-OH of a Ser residue and the N5 of the 
isoalloxazine.  Further, this enzyme is believed to perform catalysis utilizing a 1 
electron mechanism as described in Chapter 3.    
Distinguishing between the possible 1 electron mechanisms of IYD 
catalysis.  Even if the possible IYD mechanisms have been narrowed to only include 
1 electron processes, there are still a number of possibilities.  Distinguishing between 




difficult.  If IYD were to follow a 1 electron mechanism involving injection of an 
electron into the substrate’s aryl system (Figure 5-3), there would be two possibilities 
(Figure 5-4).  If the electron were injected directly into the aryl carbon with bound 
iodine, dehalogenation would be concerted and the rate of catalysis should be 
dependent upon the aryl C-X bond strength (Table 4-2).  The initial discharge of 
electrons from FMNred monitored during the single turnover assays with the 
halotyrosines presented in Chapter 4 were all similar despite the approximate 31 
kcal/mol span in energy from C-I to C-Cl (Figure 4-7).  These results do not support 
the rate of IYD catalysis being dependent upon the C-X bond energy since they do 
not appear to notably influence catalysis.  Hence, IYD likely does not utilize a 1 
electron process where the electron is injected directly to the iodine bearing aryl 
carbon.   
Alternatively, if the electron were injected into the aromatic π system of 
substrate, a radical anion intermediate would be generated (Figure 5-4).  In this case, 
dehalogenation would correlate to the electron-withdrawing ability of the substituent 
if the electron transfer is the rate determining step.  Because fluorine is the most 
electron-withdrawing of the halogens, the rate of halotyrosine dehalogenation would 
likely be fastest for MFT.  IYD likely does not utilize this 1 electron process since the 
trend for dehalogenation is opposite and MFT does not discharge electrons from 
FMNred.    
The two possible mechanisms remaining both involve dehalogenation of 
nonaromatic keto intermediates formed by tautomerization of substrate (Figure 5-5).  




injected from FMNred to the sp
3 hybridized carbon with the bound halide would be 
dependent upon the allylic C-X bond strength which spans 27 kcal/mol in energy 
from C-I to C-Cl (Table 4-2 and Figure 5-6).  Because dehalogenation following 
injection of an electron to the sp3 hybridized carbon with iodine is dependent upon the 
C-X bond strength like the aryl mechanism involving the similar injection of an 
electron to the iodine bearing carbon, the single turnover assay does not support this 
keto intermediate mechanism (Figure 4-7).   
An alternative 1 electron mechanism involving injection of an electron into 
the carbonyl of the keto intermediate (Figure 5-6) would likely correlate the rate of 
dehalogenation to the injection of the electron.  This aspect is unique to the 1 electron 
mechanism presented since the rate limiting step in dehalogenation would likely 
involve the formation of the ketyl radical.  The rate of subsequent elimination of 
halide resulting from ketyl radical formation would not be significantly altered by the 
halide substituent.  The single turnover assay is consistent with this mechanism since 
the initial rate of discharge by the halotyrosines is not considerably different. 
Therefore, dehalogenation by the ketyl radical mechanism seems the most 
likely of the possible 1 electron mechanisms.  Further, the inhibition observed by the 
N-pyridonal compounds which mimic a nonaromatic keto intermediate indicate that 
IYD stabilizes a ketyl intermediate (67).  This is because the N-pyridonal derivatives 
display orders of magnitude tighter apparent binding than Me-Tyr.   
 Lastly, there is mechanistic precedence to support ketyl radical 1 electron 
mechanism for IYD dehalogenation.  The catalytic mechanism utilized by TCE 




transfer to a substrate which could be envisioned for IYD (Figure 5-13).  Structurally, 
IYD’s tautomer intermediate is similar to the TCE reductive dehalogenase substrate 
2,3-dichloropropene (70).  Both the IYD keto intermediate and 2,3-dichloropropene 
have a halogen in an allylic position which is removed following electron injection.  
Further, dehalogenation of allylic halide by electron injection is supported by the 
dehalogenation precedence of α-haloacetophenones by the reducing agent 1,3-
dimethyl-2-phenylbenzimidazoline in organic solvent (Figure 5-14).  These 
compounds rely on the generation of a ketyl radical before dehalogenation occurs 
(108).   
Conclusion.  Overall, the 1 electron ketyl radical mechanism for IYD 
catalysis is supported by most data and precedence.  This mechanism involves 
tautomerization of substrate to a nonaromatic keto intermediate followed by injection 
of single electron from FMNred into the carbonyl of the intermediate which then 



























Figure 5-13. Possible 1-electron mechanistic similarities of A) TCE dehalogenase






deiodinase activity (Table 5-1) is consistent with a 1 electron mechanism since 5-
deazaflavins are unable to catalyze 2 electron processes.  Differentiating between the 
four possible 1 electron mechanisms is less direct.  The single turnover assay with 
halotyrosine does not support either of the aryl 1 electron mechanisms.  It also does 
not support the keto intermediate 1 electron mechanism involving direct injection into 
the sp3 hybridized carbon with the bound halide.  This is because the initial discharge 
of electrons from FMNred by the halotyrosines was not notably influenced by the 
halide substituent.  The lack of an appreciable halogen affect on the rate of discharge, 
however, does support the ketyl radical mechanism which is likely rate dependent on 
generation of the ketyl radical.  The formation of a nonaromatic keto intermediate is 
supported by the reversible inhibition of the N-pyridonal derivatives which mimic the 
keto tautomer (67). Lastly, mechanistic precedence by TCE dehalogenase (70) and 
dehalogenation of α-haloacetophenones (108) supports IYD catalysis through a ketyl 



















Figure 5-14. Mechanistic precedence of dehalogenation by ketyl radical of α-





Chapter 6:  Conclusions 
 
 
IYD remained poorly characterized for almost 50 years despite its 
physiological importance for iodide homeostasis.  The work described in this 
dissertation has provided the first molecular insights into IYD catalysis.  Prior 
discovery of the gene encoding IYD (37, 40) allowed for limited expression in 
mammalian culture, and subsequently site-directed mutagenesis to initiate 
mechanistic studies.  Despite the precedence (60, 65, 66) used for IYD catalysis 
involving nucleophilic attack of the substrate iodine by cysteine, this mechanism has 
been proven incorrect as Cys to Ala mutation variants retained deiodinase activity 
(38).  These results established IYD as a novel enzyme since no mechanistic 
precedent for flavin promoting reductive dehalogenation is available.  Because flavin 
is capable of performing both 1 and 2 electron processes, mechanisms of catalysis 
involving a single 2 electron transfer or 2 sequential 1 electron transfer had to be 
reconsidered.      
However, further investigation of these mechanisms was plagued by a lack of 
a convenient source of active and soluble protein. This was overcome by expressing a 
synthetic Mus musculus IYD gene designed for expression in Pichia pastoris, as well 
as by expressing the truncated Mus musculus IYD gene in Sf9 insect cells.  Large 
scale expression and isolation of soluble IYD from Sf9 cells provided an abundant 
supply (43 ± 8 mg of isolated IYD per L of expression culture) of highly pure enzyme 




Subsequent crystallographic studies yielded a structure of IYD at 2.0 Å (97).  
This structure confirmed IYD’s placement in the NOX/FRase structural superfamily 
and provided an understanding of congenital mutations in the IYD human gene (28, 
29).  Further, the structure showed that Cys residues are not located near the active 
site.  Additional structures with MIT and DIT substrates bound to IYD were also 
obtained and indicate that substrate binding induces the formation of an active site lid.  
This lid sequesters substrate from solvent and confers IYD’s substrate specificity for 
amino acids.  Several polar contacts from the substrate to the active site lid and the 
FMN cofactor orient the substrate parallel to the isoalloxazine of FMN with the 
substrate C-X bond directly above the C4a and N5 positions of FMN.   
IYD’s substrate recognition appears to be governed by the 3-position 
substituent as indicated by its nM binding affinity for Tyr derivatives with optimal 
electronics.  Single turnover experiments with these derivatives identified MBT and 
MCT in addition to MIT and DIT as substrates of IYD.  IYD clearly has significant 
dehalogenating power due to its ability to dehalogenate both MBT and MCT which 
have C-X bond energies significantly greater than MIT. 
The absence of observable dehalogenase activity in the IYD•5-deazaFMN 
holoenzyme indicates that IYD utilizes a catalytic mechanism involving two 
sequential electron transfers to substrate because 5-deazaflavins are incapable of 
performing 1 electron processes (87, 88).  Two 1 electron mechanisms involving a 
nonaromatic keto intermediate are consistent with the reversible inhibition observed 
with N-pyridonal compounds which mimic keto intermediate.  Single turnover assays 




have an appreciable effect on the rate of catalysis.  This supports an IYD mechanism 
involving injection of a single electron into the carbonyl of a keto intermediate which 
then facilitates dehalogenation because the rate determining step in the mechanism is 
likely the electron injection into the carbonyl.  This ketyl radical mechanism is also 
supported by the mechanistic precedence of TCE dehalogenase (70) and 
dehalogenation of α-haloacetophenones (108).  
These mechanistic studies presented were preliminary in nature and further 
investigation of the mechanism is needed.  Synthesis of substrate derivatives capable 
of trapping a 1 electron intermediate would provide additional mechanistic 
information.  Also, stopped flow kinetics experiments with a wide range of Tyr 
derivatives would aid in further distinguishing between the possible 1 electron 






A. Densitometry estimate of IYD concentrations in HEK293 cell lysates. 
HEK 293 cells expressing wild-type IYD and IYD Cys to Ala mutation variants 
were harvested following transformation.  These cells were lysed and analyzed by 
SDS-PAGE, Coomassie staining, and densitometry to determine the concentration of 
the protein. A-1) A representative SDS-PAGE analysis is presented here with IYD 
expression lysates (lane 1), a control lane of HEK293 cells lacking IYD expression 
(lane 2) and molecular weight markers (lane M).  Densitometry was performed with 
the full lane length and width in order to calculate the amount of the respective IYD 
proteins in the lysates.  A-2) A representative densitometry analysis is shown for the 
determination of IYD relative to the cell lysates where it is calculated from the 
difference in “c” between lane 1 and lane 2.  Cellular proteins “a” and “b” were used 
as controls in the calculations and varied by less than 3 % in each of the lysates.  




B. Rate of DIT deiodination by IYD and IYD Cys to Ala mutation 
variants. 
Deiodinase activity of B-1) IYD, B-2) IYD C217A, B-3) IYD C239A, and B-4) 
IYD C217A C239A from HEK293 expression lysates was determined using standard 
dithionite kinetic assays.  The data, colored according to individual assay data sets, 
was fit to the Michaelis-Menten equation using Origin 7.0. The fit and standard 
deviation error bars from the overall data points is shown in black.  Modified from 
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D. Rate of DIT deiodination by isolated IYD(ΔTM)His6.   
Deiodinase activity of IYD isolated from D-1) Pichia and D-2) Sf9 cells was 
determined using the standard steady state assays.  The data, colored according to 
individual assay data sets, was fit to the Michaelis-Menten equation using Origin 
7.0. The fit and standard deviation error bars from the overall data points are shown 
in black.  The kinetics obtained from fitting for protein isolated from A) Pichia was a 
KM of 19 ± 3 µM and a kcat of 6.9 ± 1.3 min
-1 and from B) Sf9 cells was a KM of 9 ± 
1 µM and a kcat of 4.5 ± 0.7 min








E.  Fluorescence quenching assay to measure IYD affinity for Tyr 
derivatives.   
Fluorescence emission was monitored upon titration with tyrosine derivatives.  
Binding (λex 450 and λem 527 nm) of E-1) Tyr derivatives and E-2) halotyrosine 
derivatives to IYD isolated from Sf9 cells was measured was calculated from 
fluorescence quenching by MIT, DIT, MNT, Me-Tyr, Tyr, MBT, MCT, and MFT.  
Data points are an average of 3 or more independent sets of measurements, and 
indicated error represents standard deviation at each ligand concentration. 
Dissociation constants derive from best fit (line) to either Eq. 4-1 (Tyr and Me-Tyr) 
or Eq. 4-2 (MIT, MBT, MCT, MFT, DIT) according to Origin 7.0.  See Table 4-2 for 
KD values.  Modified from McTamney and Rokita (115).  E-3) Binding of Tyr, Tyr 
in the presence of 1.5 mM free iodide, 2-iodophenol, NADPH, and nicotinic acid 
was performed with isolated IYD.  Dissociation constants were estimated as a lower 
limit from best fit (line) to either Eq. 4-1 because full binding curves could not be 
obtained due to poor solubility.  E-4) Binding of MIT to IYD•5-deazaFMN was 
calculated from fluorescence quenching (λex 399 and λem 461 nm). Data points are an 
average of 3 or more independent sets of measurements, and indicated error 
represents standard deviation at each ligand concentration.  The KD derives from best 
fit (line) to Equation 5-1 because fitting to Equation 5-2 gave an error 2.5 fold more 
than the KD value.  MIT binding to IYD isolated from Sf9 is shown for binding 















F.  Anaerobic reduction and discharge of electrons from IYD’s FMN 
cofactor by MIT. 
Single turnover assays were monitored spectrophotometrically for F-1) 
reduction and F-2) discharge of electrons from IYD’s FMN cofactor.  F-1) Anaerobic 
reduction of IYD’s active site FMN (50 µM) (─) was performed by addition of 
anaerobic dithionite (0.075 molar equivalents).  The inset graph illustrates that 1 
molar equivalent of dithionite is sufficient for full reduction of IYD’s  FMN cofactor 
(─).  F-2) Reoxidation of IYD’s fully reduced FMN occurred following serial 
additions of anaerobic MIT, which yielded the final spectrum of oxidized IYD (─).  










G.  HPLC analysis of substrate catalysis by reduced IYD under anaerobic 
conditions.   
Completed anaerobic assays for oxidation of G-1) FMNred or G-2) deazaFMN 
derivatives by respective Tyr derivatives were analyzed by reverse phase (C-18) 
HPLC with a methanol elution gradient 0-83 % in 10 mM TEAA, pH 5.5.  G-1) 
Completed assays were analyzed with 100 µL aliquots (2 molar equivalents of 
respective Tyr derivative added during assay) and were compared to appropriate 
standards (1 molar equivalent). MFT and MNT assays samples were spiked with Tyr 
standard as a control for Tyr generation.  Modified from McTamney and Rokita 
(115).  G-2) Completed deazaFMN assays were analyzed with 500 µL aliquots 
containing 1 molar equivalent of MIT added to the 5-deazaFMN assay and 6 molar 
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